

Epizyme, Inc.  
Form DEF 14A  
April 18, 2019  
**Table of Contents**

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**SCHEDULE 14A**  
**(Rule 14a-101)**  
**INFORMATION REQUIRED IN PROXY STATEMENT**  
**SCHEDULE 14A INFORMATION**  
**Proxy Statement Pursuant to Section 14(a) of the**  
**Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

**EPIZYME, INC.**

**(Exact name of registrant as specified in its charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

Edgar Filing: Epizyme, Inc. - Form DEF 14A

- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
  
- (4) Proposed maximum aggregate value of transaction:
  
- (5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- (1) Amount Previously Paid:
  
- (2) Form, Schedule or Registration Statement No.:
  
- (3) Filing Party:
  
- (4) Date Filed:

**Table of Contents**

**EPIZYME, INC.**

**400 Technology Square**

**Cambridge, Massachusetts 02139**

**NOTICE OF 2019 ANNUAL MEETING OF STOCKHOLDERS**

**To be held May 31, 2019**

You are cordially invited to attend the 2019 Annual Meeting of Stockholders, or the Annual Meeting, of Epizyme, Inc., which is scheduled to be held on Friday, May 31, 2019 at 10:00 a.m. Eastern time, at the offices of Wilmer Cutler Pickering Hale and Dorr, 60 State Street, Boston, Massachusetts 02109.

Only stockholders who owned common stock at the close of business on April 5, 2019 can vote at the Annual Meeting or any adjournment that may take place. At the Annual Meeting, the stockholders will consider and vote on the following matters:

1. Election of three class III directors to our board of directors, each to serve until the 2022 annual meeting of stockholders;
2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3. Approval on an advisory (non-binding) basis, of the compensation of our named executive officers;
4. Holding, on an advisory (non-binding) basis, an annual vote on the compensation of our named executive officers; and
5. Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

You can find more information, including the nominees for director, in the proxy statement for the Annual Meeting, which is available for viewing, printing and downloading at <http://www.edocumentview.com/epzm>. The board of directors recommends that you vote in favor of each of proposals one through three as outlined in the attached proxy statement.

Instead of mailing a paper copy of our proxy materials to all of our stockholders, we are providing access to our proxy materials over the Internet under the Securities and Exchange Commission's notice and access rules. As a result, we are sending to our stockholders a Notice of Internet Availability of Proxy Materials, or the Notice, instead of a paper copy of this proxy statement and our Annual Report for the fiscal year ended December 31, 2018, or the 2018 Annual Report. We plan to mail the Notice on or about April 18, 2019, and the Notice contains instructions on how to access

our proxy materials over the Internet. The Notice also contains instructions on how each of our stockholders can receive a paper copy of our proxy materials, including the proxy statement, our 2018 Annual Report, and a form of proxy card.

We cordially invite all stockholders to attend the Annual Meeting in person. Stockholders of record at the close of business on April 5, 2019, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. You may obtain directions to the location of the Annual Meeting by calling our offices at 617-229-5872. Whether or not you expect to attend the Annual Meeting in person, please vote your shares to ensure your representation and the presence of a quorum at

**Table of Contents**

the Annual Meeting. If you are a stockholder of record, you may vote your shares on the Internet by visiting <https://www.investorvote.com/epzm>, by telephone by calling 1-800-652-VOTE (8683) and following the recorded instructions or by completing, signing, dating, and returning a proxy card. Your vote is important regardless of the number of shares you own. If you mail your proxy card or vote by telephone or the Internet and then decide to attend the Annual Meeting to vote your shares in person, you may still do so. Your proxy is revocable in accordance with the procedures set forth in the proxy statement.

If your shares are held in street name, that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be voted.

By order of the Board of Directors,

/s/ Robert Bazemore

Robert Bazemore

*President and Chief Executive Officer*

Cambridge, Massachusetts

April 18, 2019

**Table of Contents**

**Epizyme, Inc.**

**Proxy Statement**

**Table of Contents**

	<b>Page</b>
<u>Proxy Statement</u>	1
<u>Important Information About the Annual Meeting and Voting</u>	2
<u>Proposal No. 1 Election of Class III Directors</u>	6
<u>Proposal No. 2 Ratification of the Appointment of Ernst &amp; Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2019</u>	11
<u>Corporate Governance</u>	12
<u>Executive Compensation</u>	20
<u>Proposal 3: Advisory Vote on Executive Compensation</u>	38
<u>Proposal 4: Advisory Vote on the Frequency of Future Executive Compensation Advisory Votes</u>	39
<u>Transactions with Related Persons</u>	40
<u>Principal Stockholders</u>	42
<u>Section 16(a) Beneficial Ownership Reporting Compliance</u>	45
<u>Report of the Audit Committee</u>	45
<u>Householding</u>	46
<u>Stockholder Proposals</u>	46
<u>Other Matters</u>	47

**Table of Contents**

**EPIZYME, INC.**

**400 Technology Square**

**Cambridge, Massachusetts 02139**

**617-229-5872**

**PROXY STATEMENT**

**FOR THE 2019 ANNUAL MEETING OF STOCKHOLDERS**

**to be held May 31, 2019**

This proxy statement contains information about the Annual Meeting of Stockholders of Epizyme, Inc., or the Annual Meeting, to be held on Friday, May 31, 2019 at 10:00 a.m. Eastern time, at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts, 02109. The board of directors of Epizyme is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, unless expressly stated otherwise or the context otherwise requires, the use of Epizyme, our, we or us refers to Epizyme, Inc. and its subsidiary.

All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the matters set forth in the accompanying Notice of Meeting. If you are a stockholder of record, you may change your vote or revoke your proxy at any time before it is exercised at the meeting by giving our Secretary written notice to that effect.

Instead of mailing a paper copy of our proxy materials to all of our stockholders, we are providing access to our proxy materials over the Internet under the Securities and Exchange Commission's notice and access rules. As a result, we are mailing to our stockholders a Notice of Internet Availability of Proxy Materials, or Notice, instead of a paper copy of this proxy statement and our Annual Report for the fiscal year ended December 31, 2018, or the 2018 Annual Report. We sent the Notice on or about April 18, 2019, and it contains instructions on how to access those documents over the Internet. The Notice also contains instructions on how each of our stockholders can receive a paper copy of our proxy materials, including this proxy statement, our 2018 Annual Report, and a form of proxy card.

**Important Notice Regarding the Availability of Proxy Materials for**

**the Annual Meeting of Stockholders to be Held on May 31, 2019:**

**This proxy statement and our 2018 Annual Report are**

**available for viewing, printing and downloading at <http://www.edocumentview.com/epzm>.**

**A copy of our annual report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the Securities and Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder upon written request to Epizyme, Inc. 400 Technology Square, Cambridge, Massachusetts 02139. This proxy statement and our annual report on Form 10-K for the fiscal year ended December 31, 2018 are**

also available on the SEC's website at <http://www.sec.gov>.



**Table of Contents**

**IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING**

**Purpose of the Annual Meeting**

At the Annual Meeting, our stockholders will consider and vote on the following matters:

1. Election of three class III directors to our board of directors, each to serve until the 2022 annual meeting of stockholders;
2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3. Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers;
4. Holding, on an advisory (non-binding) basis, an annual vote on the compensation of our named executive officers; and
5. Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.

As of the date of this proxy statement, we are not aware of any business to come before the meeting other than the first four items noted above.

**Board of Directors Recommendation**

Our board of directors unanimously recommends that you vote:

**FOR** the election of the three nominees to serve as class III directors on our board of directors for a three-year term;

**FOR** the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;

**FOR** the approval, on an advisory (non-binding) basis, of the compensation of our named executive officers; and

**FOR** holding, on an advisory (non-binding) basis, an annual vote on the compensation of our named executive officers.

**Availability of Proxy Materials**

The proxy materials, including this proxy statement, a proxy card and our 2018 Annual Report are available for viewing, printing and downloading on the Internet at <http://www.edocumentview.com/epzm>.

**Who Can Vote at the Annual Meeting**

Only stockholders of record at the close of business on the record date of April 5, 2019, are entitled to receive notice of the Annual Meeting and to vote the shares of our common stock that they held on that date. As of April 5, 2019, there were 90,810,988 shares of common stock issued and outstanding. Each share of common stock is entitled to one vote on each matter properly brought before the Annual Meeting.

**Difference between a stockholder of record and a beneficial owner of shares held in street name**

*Stockholder of Record.* If your shares are registered directly in your name with our transfer agent, Computershare, then you are considered a stockholder of record of those shares. You may vote your shares by proxy prior to the Annual Meeting by following the instructions contained in the Notice and in the section titled How to Vote on page 3 of this proxy statement.

## **Table of Contents**

*Beneficial Owners of Shares Held in Street Name.* If your shares are held in a brokerage account or by a bank, trust or other nominee or custodian, then you are considered the beneficial owner of those shares, which are held in street name. The organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to instruct that organization as to how to vote the shares held in your account by following the instructions contained on the voting instruction card provided to you by that organization.

### **Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?**

We are pleased to comply with the SEC rules that allow companies to distribute their proxy materials over the Internet under the notice and access approach. As a result, on or about April 18, 2019, we sent our stockholders and beneficial owners a copy of the Notice instead of paper copies of this proxy statement, our proxy card, and our 2018 Annual Report. Detailed instructions on how to access these materials via the Internet may be found in the Notice. This proxy statement and our 2018 Annual Report are available for viewing, printing and downloading on the Internet at <http://www.edocumentview.com/epzm>.

### **How to Vote**

If you are a stockholder of record, you can vote your shares in one of two ways: either by proxy or in person at the Annual Meeting. If you choose to vote by proxy, you may do so by telephone, via the Internet or by mail. Each of these methods is explained below.

*By Telephone.* You may transmit your proxy over the phone by calling 1-800-652-VOTE (8683) and following the instructions provided in the Notice and on the proxy card.

*Via the Internet.* You may transmit your proxy via the Internet by following the instructions provided in the Notice and on the proxy card.

*By Mail.* If you requested printed copies of proxy materials, you can vote by mailing your proxy card as described in the proxy materials.

*In Person at the Annual Meeting.* You may vote in person at the Annual Meeting. We will give you a ballot when you arrive. If you are the beneficial owner of shares held in street name and you wish to vote in person at the Annual Meeting, you must obtain a legal proxy from the organization that holds your shares and present it with your ballot to the inspector of election at the Annual Meeting. Even if you plan to attend the Annual Meeting, we urge you to vote your shares by proxy in advance of the Annual Meeting so that if you should become unable to attend the Annual Meeting your shares will be voted as directed by you.

Telephone and Internet voting for stockholders of record will be available up until 1:00 a.m. Eastern time on May 31, 2019, and mailed proxy cards must be received by May 30, 2019 in order to be counted at the Annual Meeting. If the Annual Meeting is adjourned or postponed, these deadlines may be extended.

The voting deadlines and availability of telephone and Internet voting for beneficial owners of shares held in street name will depend on the voting processes of the organization that holds your shares. Therefore, we urge you to carefully review and follow the voting instruction card and any other materials that you receive from that organization.

**Can I Vote My Shares by Filling Out and Returning the Notice of Internet Availability of Proxy Materials?**

No. The Notice contains instructions on how to vote via the Internet, by telephone, by requesting and returning a paper proxy card, or by submitting a ballot in person at the Annual Meeting.

## **Table of Contents**

### **Quorum**

A quorum of stockholders is necessary to hold a valid meeting. Our amended and restated by-laws provide that a quorum will exist if stockholders holding a majority of the shares of stock issued and outstanding and entitled to vote are present at the meeting in person or by proxy. If a quorum is not present, the meeting may be adjourned until a quorum is obtained.

Abstentions and broker non-votes count as present for establishing a quorum but will not be counted as votes cast. Broker non-votes occur when your broker or other nominee submits a proxy for your shares (because the broker or other nominee has received instructions from you on one or more proposals, but not all proposals, or has not received instructions from you but is entitled to vote on a particular discretionary matter) but does not indicate a vote for a particular proposal because the broker or other nominee either does not have the authority to vote on that proposal and has not received voting instructions from you or has discretionary authority but chooses not to exercise it.

### **Ballot Measures Considered Discretionary and Non-Discretionary**

The election of directors (Proposal No. 1) is a matter considered non-discretionary under applicable rules. A broker or other nominee cannot vote without instructions on non-discretionary matters, and therefore there may be broker non-votes on Proposal No. 1.

The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2019 (Proposal No. 2) is a matter considered discretionary under applicable rules. A broker or other nominee may generally exercise discretionary authority and vote on discretionary matters. If they exercise this discretionary authority, no broker non-votes are expected to occur in connection with Proposal No. 2.

Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers (Proposal No. 3) is a matter considered non-discretionary under applicable rules. A broker or other nominee cannot vote without instructions on non-discretionary matters, and therefore there may be broker non-votes on Proposal No. 3.

Holding, on an advisory (non-binding) basis, a vote on the frequency of future executive compensation advisory votes of the compensation of our named executive officers (Proposal No. 4) is a matter considered non-discretionary under applicable rules. A broker or other nominee cannot vote without instructions on non-discretionary matters, and therefore there may be broker non-votes on Proposal No. 4.

### **Votes Required to Elect a Director, Ratify Appointment of Ernst & Young LLP and Approve the Advisory Vote on Executive Officer Compensation and the Frequency of Future Executive Compensation Advisory Votes**

To be elected, a director must receive a plurality of the votes cast by stockholders entitled to vote at the meeting (Proposal No. 1).

The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm (Proposal No. 2); the approval of the advisory vote on executive compensation (Proposal 3); and the approval of one of the three frequency options under the advisory vote on the frequency of future executive compensation advisory votes (Proposal 4) require the affirmative vote of a majority of the shares of common stock present or represented by proxy and voted for or against such matter.

Shares which abstain and broker non-votes will not be counted as votes in favor of, or with respect to, these proposals and will also not be counted as votes cast. Accordingly, abstentions and broker non-votes will have no effect on the outcome of these proposals.

## **Table of Contents**

### **Method of Counting Votes**

Each holder of common stock is entitled to one vote at the Annual Meeting on each matter to come before the Annual Meeting, including the election of directors, for each share held by such stockholder as of the record date. Votes cast in person at the Annual Meeting or by proxy by mail, via the Internet or by telephone will be tabulated by the inspector of election appointed for the Annual Meeting, who will also determine whether a quorum is present.

### **Revoking a Proxy; Changing Your Vote**

If you are a stockholder of record, you may revoke your proxy before the vote is taken at the meeting:

by submitting a new proxy with a later date before the applicable deadline either signed and returned by mail or transmitted using the telephone or Internet voting procedures described in the **How to Vote** section above;

by voting in person at the meeting; or

by filing a written revocation with our corporate Secretary.

If your shares are held in street name, you may submit new voting instructions by contacting your broker or other organization holding your account. You may also vote in person at the Annual Meeting, which will have the effect of revoking any previously submitted voting instructions, if you obtain a legal proxy from the organization that holds your shares as described in the **How to Vote** section above.

Your attendance at the Annual Meeting will not automatically revoke your proxy.

### **Costs of Proxy Solicitation**

We will bear the costs of soliciting proxies. Our directors, officers and regular employees, without additional remuneration, may solicit proxies by mail, telephone, facsimile, email, personal interviews and other means.

### **Voting Results**

We plan to announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K to be filed with the SEC within four business days following the Annual Meeting.

**Table of Contents**

**PROPOSAL NO. 1 ELECTION OF THREE CLASS III DIRECTORS**

Our board of directors currently consists of nine members. In accordance with the terms of our certificate of incorporation and by-laws, our board of directors is divided into three classes (class I, class II and class III), with members of each class serving staggered three-year terms. The members of the classes are divided as follows:

the class I directors are Andrew R. Allen, M.D., Ph.D., Kenneth Bate and Robert Bazemore, and their term expires at the annual meeting of stockholders to be held in 2020;

the class II directors are Kevin T. Conroy, Carl Goldfischer, M.D., and Beth Seidenberg, M.D., and their term expires at the annual meeting of stockholders to be held in 2021; and

the class III directors are Michael F. Giordano, M.D., David M. Mott, and Richard F. Pops, and their term expires at the Annual Meeting;

Upon the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires.

Our certificate of incorporation and by-laws provide that the authorized number of directors may be changed only by resolution of our board of directors. Our certificate of incorporation and by-laws also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office.

Our board of directors has nominated Michael F. Giordano, M.D., David M. Mott, and Richard F. Pops for election as class III directors at the Annual Meeting. Each of the nominees is presently a director, and each has indicated a willingness to continue to serve as director, if elected. If a nominee becomes unable or unwilling to serve, however, the proxies may be voted for substitute nominees selected by our board of directors.

We have no formal policy regarding board diversity. Our priority in selection of board members is identification of members who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the competitive landscape.



**Table of Contents****Nominees for Election as Class III Directors**

Biographical information as of April 1, 2019, including principal occupation and business experience during the last five years, for our nominees for election as class III directors at our Annual Meeting is set forth below.

	<b>Age</b>
<b><i>Class III Directors (Term Expires at Annual Meeting)</i></b>	
<p><b><i>Michael F. Giordano, M.D.</i></b> has served as a director since March 8, 2018. Dr. Giordano served as a clinical advisor to us from December 2017 to August 2018. From 1999 to 2017, Dr. Giordano worked at Bristol-Myers Squibb, or BMS, most recently serving as senior vice president and head of development, oncology and immuno-oncology. In this role, he was responsible for the development strategy for this therapeutic area, as well as for the direction of eight teams working on innovative medicines to improve the standard of care for patients, including Opdivo®, Yervoy®, Empliciti, Ixempra®, and Sprycel®. Dr. Giordano also held positions of increasing responsibility within the BMS research and development organization, leading the development of more than a dozen molecules in the United States, Europe and Asia. From 1990 to 1999, he served as assistant professor of medicine and founding director of the Cornell Clinical Trials Unit, a National Institutes of Health and Industry-supported AIDS clinical trials center at New York Hospital-Cornell University Medical Center. He earned his M.D. and completed his residency and fellowship training at New York Presbyterian Weill Cornell Medical Center, and received his B.A. in natural sciences from The Johns Hopkins University. We believe that Dr. Giordano's extensive experience in oncology and immuno-oncology at BMS, as well as his experience as a clinical advisor to us, provide him with the qualifications and skills to serve as a director of our company.</p>	61
<p><b><i>David M. Mott</i></b> has served as a director since December 2009 and as Chairman of the board since April 2016. Mr. Mott has served as a general partner of New Enterprise Associates, Inc., an investment firm focused on venture capital and growth equity investments and a holder of more than 5% of our voting securities, since September 2008, where he leads the healthcare investing practice. From 1992 until 2008, Mr. Mott worked at MedImmune, Inc., or MedImmune, a biotechnology company and subsidiary of AstraZeneca Plc, or AstraZeneca, and served in numerous roles during his tenure, including most recently as Chief Executive Officer from October 2000 to July 2008. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca from June 2007 to July 2008 following AstraZeneca's acquisition of MedImmune in June 2007. Mr. Mott also serves as the Chairman of the board of directors of Ardelyx, Inc. and Adaptimmune and serves on the boards of several private biopharmaceutical companies. Mr. Mott received a B.A. from Dartmouth College. We believe that Mr. Mott's extensive experience in the life sciences industry as a senior executive and venture capitalist, as well as his service on the boards of directors of other life sciences companies, provide him with the qualifications and skills to serve as a director of our company.</p>	53
<p><b><i>Richard F. Pops</i></b> has served as a director since September 2008. Mr. Pops has served as Chief Executive Officer of Alkermes plc, or Alkermes, a publicly traded biopharmaceutical company, since 2009 and from 1991 to 2007. Mr. Pops has been a director of Alkermes since February 1991 and has been Chairman of the board of directors since April 2007. Mr. Pops also serves on the board of directors of Neurocrine Biosciences, Inc. and Acceleron Pharma, Inc. Mr. Pops received a B.A. in economics from Stanford University. We believe that Mr. Pops' leadership experience, including as chief executive officer of a public biopharmaceutical company, his business judgment and his industry knowledge provide him with the qualifications and skills to serve as a director of our company.</p>	56

The proxies will be voted in favor of the nominees unless a contrary specification is made in the proxy. The nominees have consented to serve as our directors if elected. However, if any nominee is unable for any reason to serve as a director, proxies may be voted for one or more substitutes who will be designated by our board of directors.

**The board of directors recommends voting FOR the election of each of Michael F. Giordano, M.D., David M. Mott, and Richard F. Pops as class III directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2022.**

**Table of Contents****Directors Continuing in Office**

Biographical information as of April 1, 2019, including principal occupation and business experience during the last five years, for our directors continuing in office after the Annual Meeting is set forth below.

	<b>Age</b>
<b><i>Class I Directors (Term Expires at 2020 Annual Meeting)</i></b>	
<p><b>Andrew R. Allen, M.D., Ph.D.</b> has served as a director since June 2014. Dr. Allen has served as the Chief Executive Officer and President of Gritstone Oncology, Inc., an immunotherapy company that he co-founded, since August 2015. From April 2009 to August 2015, Dr. Allen served as the Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer of Clovis Oncology, Inc., a biopharmaceutical company that he co-founded. Prior to co-founding Clovis, he served in the same role at Pharmion Corporation, a pharmaceutical company, beginning in 2006. From 2004 to 2006, Dr. Allen served as Vice President of BioPharma Development and Head of the Oncology Therapeutic Unit for Chiron Corporation, a biotechnology company. Prior to that, Dr. Allen served as global project head in Abbott Laboratories oncology franchise, and he progressed through positions of increasing responsibility at the management consulting firm McKinsey &amp; Company, with a focus on oncology strategy. Dr. Allen qualified in medicine at Oxford University and earned his Ph.D. from the Imperial College of Science, Technology and Medicine in London. Dr. Allen also obtained post-graduate internal medicine qualification as a Member of Royal College of Physicians. We believe that Dr. Allen's extensive experience in the pharmaceutical industry and his expertise in oncology clinical development and oncology strategy provide him with the qualifications and skills to serve as a director of our company.</p>	52
<p><b>Kenneth Bate</b> has served as a director since December 2014. Mr. Bate has served as an independent consultant in the biotechnology field since 2012. From 2009 to 2012, Mr. Bate served as President and Chief Executive Officer of Archemix, Inc., or Archemix, a privately-held biotechnology company. Prior to Archemix, from 2006 to 2009, Mr. Bate served in various positions at NitroMed, Inc., a pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Chief Financial Officer of Millennium Pharmaceuticals, where he headed the commercial organization. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, he was with Biogen Inc., a biotechnology company, first as their Chief Financial Officer, and then as head of the commercial organization responsible for launching the multiple sclerosis business. Mr. Bate serves on the board of directors of AVEO Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc. and Genocea Biosciences, Inc. Mr. Bate received his B.A. in chemistry from Williams College and his M.B.A. from the Wharton School of the University of Pennsylvania. We believe that Mr. Bate's extensive financial and leadership experience, his experience as an executive and his service on the board of directors of numerous public and privately held companies provide him with the qualifications and skills to serve as a director of our company.</p>	68
<p><b>Robert B. Bazemore Jr.</b> has served as a director and our President and Chief Executive Officer since September 2015. From September 2014 to June 2015, Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders. Prior to joining Synageva, Mr. Bazemore served in increasing levels of responsibility at Johnson &amp; Johnson, a healthcare company, including Vice President of Centocor Ortho Biotech Sales &amp; Marketing from</p>	51

Edgar Filing: Epizyme, Inc. - Form DEF 14A

2008 to 2010, President of Janssen Biotech from January 2010 to October 2013 and Vice President of Global Surgery at Ethicon from October 2013 to September 2014. Prior to Johnson & Johnson, Mr. Bazemore worked at Merck & Co., Inc., or Merck, for eleven years, where he served in a variety of roles in medical affairs, sales and marketing. Mr. Bazemore serves on the board of directors of Ardelyx, Inc. and Neon Therapeutics, Inc. He received a B.S. in biochemistry from the University of Georgia. We believe that Mr. Bazemore's extensive experience in the pharmaceutical industry, his experience as an executive, and his past service on the board of directors of a life sciences industry group, provide him with the qualifications and skills to serve as a director of our company.

**Table of Contents**

Age

***Class II Directors (Term Expires at 2021 Annual Meeting)***

**Kevin T. Conroy** has served as a director since February 2017. Mr. Conroy is currently the President, Chief Executive Officer and Chairman of the Board of Directors of Exact Sciences Corporation, or Exact Sciences, a molecular diagnostics company. Mr. Conroy was named Chairman of the Board of Exact Sciences in March 2014, and has served as President and Chief Executive Officer since April 2009 and as a director since March 2009. Prior to joining Exact Sciences, Mr. Conroy served in multiple executive leadership positions at Third Wave Technologies, or Third Wave, a molecular diagnostic testing company, including President and Chief Executive Officer from December 2005 until the acquisition of Third Wave by Hologic, Inc. in July 2008. He joined Third Wave in July 2004 and served as General Counsel from October 2004 until December 2005. Prior to Third Wave, Mr. Conroy served as Intellectual Property Counsel at GE Healthcare, a medical imaging and diagnostics company and a division of General Electric Company. Before joining GE Healthcare, Mr. Conroy was the chief operating officer of two early-stage, venture-backed technology companies. Prior to that, he was an intellectual property litigator at McDermott Will & Emery and Pattishall, McAuliffe, Newbury, Hilliard and Geraldson, where he was a partner. Mr. Conroy received a B.S. in electrical engineering from Michigan State University and a J.D. from the University of Michigan Law School. We believe that Mr. Conroy's extensive executive experience in the life sciences industry and his service on the board of directors of a life sciences company provide him with the qualifications and skills to serve as a director of our company. 53

**Carl Goldfischer, M.D.** has served as a director since September 2009. Dr. Goldfischer has served as an Investment Partner, Managing Director, member of the board of directors and member of the executive committee of Bay City Capital LLC, or Bay City Capital, a life sciences investment firm and a holder of more than 5% of our voting securities, since January 2000. Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer of ImClone Systems Incorporated, a biopharmaceutical company. Since 2004, Dr. Goldfischer has served on the board of directors of EnteroMedics Inc., a publicly traded medical device company. He has previously served on the board of directors of two other publicly traded companies, MAP Pharmaceuticals, Inc. from 2004 to 2011 and Poniard Pharmaceuticals, Inc. from 2000 to 2012. Dr. Goldfischer received a B.A. from Sarah Lawrence College and an M.D. with honors in Scientific Research from Albert Einstein College of Medicine. We believe that Dr. Goldfischer's extensive finance and investment experience, his experience as an executive and his service on the board of directors of numerous public and privately held companies provide him with the qualifications and skills to serve as a director of our company. 60

**Beth Seidenberg, M.D.** has served as a director since February 2008. Dr. Seidenberg has been a partner at Kleiner Perkins Caufield & Byers, or Kleiner Perkins, a venture capital firm and a holder of more than 5% of our voting securities, since May 2005, where she primarily focuses on life sciences investing. Prior to joining Kleiner Perkins, Dr. Seidenberg was the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc., a biotechnology company. In addition, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, and Merck. Dr. Seidenberg serves on the board of directors of Atara Biotherapeutics. Dr. Seidenberg received a B.S. from Barnard College and an M.D. from the University of Miami School of Medicine and completed her post-graduate training at the Johns Hopkins University, George Washington University and the National Institutes of Health. We believe that Dr. Seidenberg's extensive experience in the life sciences industry as a senior executive and venture capitalist, as well as her training as a physician, provide her with the qualifications and skills to serve as a director of our company. 61

## Edgar Filing: Epizyme, Inc. - Form DEF 14A

There are no family relationships between or among any of our directors or executive officers. The principal occupation and employment during the past five years of each of our directors was carried on, in each case except as specifically identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our directors and any other person or persons pursuant to which he or she is to be selected as a director.

There are no material legal proceedings to which any of our directors is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or any of our subsidiaries.

**Table of Contents****Executive Officers Who Are Not Directors**

Biographical information as of March 1, 2019 for our executive officers who are not directors is listed below.

	<b>Age</b>
<p><b>Matthew E. Ros</b> has served as our Chief Strategy and Business Officer since September 2018 and as our Chief Operating Officer from May 2016 to September 2018. Prior to joining us, from September 2010 to May 2016, Mr. Ros served in increasing levels of responsibility at Sanofi, a multinational pharmaceutical company, most recently as Chief Operating Officer/Global Head of the Oncology Business unit from December 2014 to May 2016. Prior to that role, Mr. Ros served in the rare disease business of Genzyme, a Sanofi company, where he served as Vice President and Franchise Head of its Pompe disease unit from September 2012 to December 2014, and also served as the Associate Vice President and Iniparib Global Brand Leader in Sanofi's Oncology Business unit from September 2010 to September 2012. From October 2007 to June 2010, Mr. Ros served at ARIAD Pharmaceuticals, Inc., a global oncology company, most recently as Senior Vice President, Commercial Operations. He started his pharmaceutical career in Bristol-Myers Squibb's Oncology Division, serving in roles with increasing responsibility from 1990 to 2007. He received a B.S. from the State University of New York, College at Plattsburgh and completed the Executive Education Program in Finance and Accounting for the Non-Financial Manager at Wharton School of the University of Pennsylvania.</p>	52
<p><b>Dr. Shefali Agarwal</b> has served as our Chief Medical Officer since joining us in June 2018. Prior to joining us, Dr. Agarwal held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as Chief Medical Officer at SQZ Biotech, a biotechnology company developing cell therapies for patients with a wide range of diseases, from July 2017 to May 2018 and as a non-executive advisor from May 2018 to July 2018, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Dr. Agarwal also held leadership positions at Curis, Inc. a biotechnology company developing therapeutics for the treatment of cancer, from July 2016 to July 2017 and TESARO, Inc., an oncology-focused biopharmaceutical company, from July 2013 to July 2017. At Curis, Inc., Dr. Agarwal oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At TESARO, Inc., Dr. Agarwal led the New Drug Application and European Medicines Agency submissions for ZEJULA® (niraparib) in ovarian cancer. Dr. Agarwal also held positions of increasing responsibility at Covidien plc, a medical devices and health care products company, from April 2010 to December 2011, AVEO Pharmaceuticals, Inc., a biopharmaceutical company advancing targeted oncology medicines, from December 2011 to July 2013 and Pfizer Inc., a pharmaceutical company with a wide range of treatments, from June 2005 to April 2010. Dr. Agarwal received her MBBS medical degree from Karnataka University's Mahadevappa Rampure Medical School in India, Master's Degree in Public Health from Johns Hopkins University, where she led clinical research in the Department of Anesthesiology and Critical Care Medicine, and a Master of Science degree in Business from the University of Baltimore's Merrick School of Business.</p> <p>The principal occupation and employment during the past five years of each of our executive officers was carried on, in each case except as specifically identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our executive officers and any other person or persons pursuant to which he or she was or is to be selected as an executive officer.</p>	45

Edgar Filing: Epizyme, Inc. - Form DEF 14A

There are no material legal proceedings to which any of our executive officers is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or any of our subsidiaries.



**Table of Contents**

**PROPOSAL NO. 2 RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP  
AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE  
FISCAL YEAR ENDING DECEMBER 31, 2019**

Our stockholders are being asked to ratify the appointment by the audit committee of the board of directors of Ernst & Young LLP as our independent registered public accounting firm. Ernst & Young LLP has served as our independent registered public accounting firm since 2009.

The audit committee is solely responsible for appointing our independent registered public accounting firm for the fiscal year ending December 31, 2019. Stockholder approval is not required to appoint Ernst & Young LLP as our independent registered public accounting firm. However, the board of directors believes that submitting the appointment of Ernst & Young LLP to the stockholders for ratification is consistent with good corporate governance. If the stockholders do not ratify this appointment, the audit committee will reconsider whether to retain Ernst & Young LLP. If the appointment of Ernst & Young LLP is ratified, the audit committee, in its discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of our company and our stockholders.

A representative of Ernst & Young LLP is expected to be present at the Annual Meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from our stockholders.

We incurred the following fees from Ernst & Young LLP for the audit of the consolidated financial statements and for other services provided during the years ended December 31, 2018 and 2017.

	<b>2018</b>	<b>2017</b>
Audit fees (1)	\$ 1,010,000	\$ 555,000
Audit-related fees		
Tax fees		
All other fees		
<b>Total fees</b>	<b>\$ 1,010,000</b>	<b>\$ 555,000</b>

- (1) Audit fees consist of fees for the audit of our annual financial statements, the review of the interim financial statements included in our quarterly reports on Form 10-Q, and other professional services provided in connection with any registration statements filed with the SEC.

**Audit Committee Pre-Approval Policy and Procedures**

Our audit committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our independent registered public accounting firm. This policy provides that we will not engage our independent registered public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by our audit committee or the engagement is entered into pursuant to the pre-approval procedure described below.

From time to time, our audit committee may pre-approve specified types of services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months. Any such pre-approval is detailed as to the particular service or type of services to be provided and is also generally subject to a maximum dollar amount.

During our 2018 and 2017 fiscal years, no services were provided to us by Ernst & Young LLP other than in accordance with the pre-approval policies and procedures described above.

**The board of directors recommends voting FOR Proposal No. 2 to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.**

**Table of Contents**

**CORPORATE GOVERNANCE**

**Director Nomination Process**

Our nominating and corporate governance committee is responsible for identifying individuals qualified to serve as directors, consistent with criteria approved by our board, and recommending the persons to be nominated for election as directors, except where we are legally required by contract, law or otherwise to provide third parties with the right to nominate director candidates.

The process followed by our nominating and corporate governance committee to identify and evaluate director candidates includes requests to board members and others for recommendations, meetings from time to time to evaluate biographical information and background material relating to potential candidates and interviews of selected candidates by members of the committee and our board. While there are no specific minimum qualifications for a committee-recommended nominee to our board of directors, the qualifications, qualities and skills that our nominating and corporate governance committee believes must be met by a committee-recommended nominee for a position on our board of directors are as follows:

Nominees should have a reputation for integrity, honesty and adherence to high ethical standards.

Nominees should have demonstrated business acumen, experience and ability to exercise sound judgments in matters that relate to our current and long-term objectives and should be willing and able to contribute positively to our decision-making process.

Nominees should have a commitment to understand our company and our industry and to regularly attend and participate in meetings of our board of directors and its committees.

Nominees should have the interest and ability to understand the sometimes conflicting interests of our various constituencies, which include stockholders, employees, customers, governmental units, creditors and the general public, and to act in the interests of all stockholders.

Nominees should not have, nor appear to have, a conflict of interest that would impair the nominee's ability to represent the interests of all of our stockholders and to fulfill the responsibilities of a director.

Nominees shall not be discriminated against on the basis of race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. The value of diversity on our board of directors is considered.

Nominees should typically be able to serve for at least three years before reaching the age of 75. Stockholders may recommend individuals to the nominating and corporate governance committee for consideration as potential director candidates. Any such proposals should be submitted to our corporate Secretary at our principal

executive offices and should include appropriate biographical and background material to allow the nominating and corporate governance committee to properly evaluate the potential director candidate and the number of shares of our stock beneficially owned by the stockholder proposing the candidate. The specific requirements for the information that is required to be provided for such recommendations to be considered are specified in our by-laws and must be received by us no later than the date referenced below under the heading Stockholder Proposals. Assuming that biographical and background material has been provided on a timely basis, any recommendations received from stockholders will be evaluated in the same manner as potential nominees proposed by the nominating and corporate governance committee. If our board of directors decides to nominate a stockholder-recommended candidate and recommends his or her election, then his or her name will be included on our proxy card for the next annual meeting.

### **Director Independence**

Applicable Nasdaq rules require a majority of a listed company's board of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq rules require that, subject to specified

---

**Table of Contents**

exceptions, each member of a listed company's audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act and that compensation committee members satisfy independence criteria set forth in Rule 10C-1 under the Exchange Act. Under applicable Nasdaq rules, a director will only qualify as an independent director if, in the opinion of the listed company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In addition, in affirmatively determining the independence of any director who will serve on a company's compensation committee, Rule 10C-1 under the Exchange Act requires that a company's board of directors must consider all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director's ability to be independent from management in connection with the duties of a compensation committee member, including: the source of compensation to the director, including any consulting, advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates.

In March 2019, our board of directors undertook a review of the composition of our board of directors and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors determined that each of our directors, with the exceptions of Mr. Bazemore and Dr. Giordano, are independent directors as defined under applicable Nasdaq rules. In making such determination, our board of directors considered the relationships that each such director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each director. Mr. Bazemore is not an independent director under these rules because he is currently serving as our president and chief executive officer. Dr. Giordano is not an independent director under these rules because he has received more than \$120,000 in consulting fees during a 12 month period within the last three years.

**Board Committees**

Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Each of the audit committee, compensation committee and nominating and corporate governance committee operates under a charter, and each such committee reviews its respective charter at least annually. A current copy of the charter for each of the audit committee, compensation committee and the nominating and corporate governance committee is posted on the corporate governance section of the Investor Center on our website, which is located at <http://www.epizyme.com>.

***Audit Committee***

The members of our audit committee are Dr. Goldfischer, Mr. Bate and Mr. Pops. Dr. Goldfischer is chair of the audit committee. Our audit committee met five times during 2018. Our audit committee's responsibilities include:

appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;

Edgar Filing: Epizyme, Inc. - Form DEF 14A

overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from that firm;

reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures;

**Table of Contents**

monitoring our internal control over financial reporting, disclosure controls and procedures and code of conduct;

overseeing our internal audit function, if any;

discussing our risk management policies;

establishing procedures for the receipt and retention of accounting-related complaints and concerns;

meeting independently with our internal audit staff, if any, our independent registered public accounting firm and management;

reviewing and approving or ratifying any related person transactions; and

preparing the audit committee report required by SEC rules.

All audit and non-audit services, other than *de minimis* non-audit services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee.

Our board of directors has determined that Dr. Goldfischer and Mr. Bate are each an audit committee financial expert as defined in applicable SEC rules. We believe that the composition of our audit committee meets the requirements for independence under current Nasdaq and SEC rules and regulations.

***Compensation Committee***

The members of our compensation committee are Mr. Mott, Dr. Allen, and Dr. Seidenberg. Mr. Mott is chair of the compensation committee. Our compensation committee met four times during 2018. Our compensation committee's responsibilities include:

reviewing and approving, or making recommendations to our board of directors with respect to, our chief executive officer's compensation;

reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of our other executive officers;

overseeing the evaluations of our senior executives;

Edgar Filing: Epizyme, Inc. - Form DEF 14A

reviewing and making recommendations to our board of directors with respect to management succession planning;

overseeing and administering our cash and equity incentive plans;

reviewing and making recommendations to our board of directors with respect to director compensation;

reviewing and discussing annually with management our Compensation Discussion and Analysis disclosure; and

preparing the compensation committee report if and to the extent then required by SEC rules.

Our compensation committee may delegate to one or more executive officers the power to grant options or other stock awards pursuant to our incentive plans to employees of the company who are not executive officers or senior vice presidents.

We believe that the composition of our compensation committee meets the requirements for independence under current Nasdaq and SEC rules and regulations. Our board of directors has determined that Mr. Mott, Dr. Allen, and Dr. Seidenberg are independent as currently defined in applicable Nasdaq listing standards.



## **Table of Contents**

### *Compensation Committee Interlocks and Insider Participation*

During 2018, the members of our compensation committee were Mr. Mott, Dr. Allen, and Dr. Seidenberg. None of the members of our compensation committee is an officer or employee of our company, nor have they ever been an officer or employee of our company. None of our executive officers has served as a director or member of the compensation committee (or other committee serving an equivalent function) of any other entity whose executive officers served as one of our directors or a member of the compensation committee. Except as set forth in the Transactions with Related Persons section with respect to entities affiliated with Mr. Mott, none of the members of the compensation committee (or his or her immediate family members) had a direct or indirect material interest in a transaction with the company involving more than \$120,000.

### *Nominating and Corporate Governance Committee*

The members of our nominating and corporate governance committee are Dr. Goldfischer, Mr. Conroy and Dr. Seidenberg. Dr. Goldfischer is chair of the nominating and corporate governance committee. Our nominating and corporate governance committee met once during 2018 and met periodically on an informal basis to discuss management and Board staffing decisions. Our nominating and corporate governance committee's responsibilities include:

identifying individuals qualified to become members of our board of directors;

recommending to our board of directors the persons to be nominated for election as directors and to each of our board's committees;

developing and recommending to our board of director's corporate governance guidelines; and

overseeing an annual evaluation of our board of directors.

We believe that the composition of our nominating and corporate governance committee meets the requirements for independence under current Nasdaq and SEC rules and regulations.

### **Board and Committee Meetings Attendance**

Our Board recognizes the importance of director attendance at Board and committee meetings. The full board of directors met eleven times during 2018. During 2018, each member of the board of directors attended in person or participated in 75% or more of the aggregate of (i) the total number of meetings of the board of directors (held during the period for which such person has been a director) and (ii) the total number of meetings held by all committees of the board of directors on which such person served (during the periods that such person served).

### **Director Attendance at Annual Meeting of Stockholders**

Directors are responsible for attending the annual meeting of stockholders. Four members of our board of directors attended the 2018 annual meeting of stockholders.

**Code of Business Conduct and Ethics**

We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code of business conduct and ethics is posted on the corporate governance section of the Investor Center on our website, which is located at <http://www.epizyme.com>. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.

## Table of Contents

### **Corporate Governance Guidelines**

Our board of directors has adopted corporate governance guidelines to assist in the exercise of its duties and responsibilities and to serve the best interests of our company and our stockholders. The guidelines provide that:

our board's principal responsibility is to oversee the management of our company;

a majority of the members of our board must be independent directors;

the independent directors meet in executive session at least twice a year;

directors have full and free access to management and, as necessary, independent advisors; and

our nominating and corporate governance committee will oversee an annual self-evaluation of the board to determine whether it and its committees are functioning effectively.

A copy of the corporate governance guidelines is posted under the heading "Corporate Governance" on the Investor Relations section of our website, which is located at <http://www.epizyme.com>.

### **Board Leadership Structure and Board's Role in Risk Oversight**

In April 2016, we appointed David M. Mott, an independent director under applicable Nasdaq rules, as chairman of the board. Prior to the appointment of Mr. Mott as chairman of the board, we did not have a chairman of the board. Mr. Mott previously served as our lead independent director and, in that capacity, served in a role similar to that of a chairman of the board. Separating the duties of the chairman of the board from the duties of the chief executive officer allows our chief executive officer to focus on our day-to-day business, while allowing the chairman of the board to lead the board of directors in its fundamental role of providing advice to and independent oversight of management. Specifically, our chairman of the board runs meetings of our independent directors, facilitates communications between management and the board of directors and assists with other corporate governance matters. Our board of directors believes that this structure ensures a greater role for the independent directors in the oversight of our company and active participation of the independent directors in setting agendas and establishing priorities and procedures for the work of our board of directors. Our board of directors believes its administration of its risk oversight function has not affected its leadership structure. Our board of directors believes that we have an appropriate leadership structure for us at this time which demonstrates our commitment to good corporate governance.

Risk is inherent with every business and how well a business manages risk can ultimately determine its success. We face a number of risks, including those described under "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2018. Our board of directors is actively involved in oversight of risks that could affect us. This oversight is conducted primarily by our full board of directors, which has responsibility for general oversight of risks.

Our board of directors oversees our risk management processes directly and through its committees. Our management is responsible for risk management on a day-to-day basis and our board and its committees oversee the risk management activities of management. Our board of directors satisfies this responsibility through full reports by each

committee chair regarding the committee's considerations and actions, as well as through regular reports directly from officers responsible for oversight of particular risks within our company. Our audit committee oversees risk management activities related to financial controls and legal and compliance risks. Our compensation committee oversees risk management activities relating to our compensation policies and practices. Our nominating and corporate governance committee oversees risk management activities relating to board composition and management succession planning. In addition, members of our senior management team attend our quarterly board meetings and are available to address any questions or concerns raised by the board on risk management and any other matters. Our board of directors believes that full and open communication between management and the board of directors is essential for effective risk management and oversight.

**Table of Contents****Communication with Our Directors**

Any interested party with concerns about our company may report such concerns to the board of directors, or the chairman of our board of directors, or otherwise the chairman of the nominating and corporate governance committee, by submitting a written communication to the attention of such director at the following address:

c/o Epizyme, Inc.

400 Technology Square

Cambridge, Massachusetts 02139

United States

You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a stockholder, customer, supplier, or other interested party.

A copy of any such written communication may also be forwarded to our legal counsel and a copy of such communication may be retained for a reasonable period of time. The director may discuss the matter with our legal counsel, with independent advisors, with non-management directors, or with our management, or may take other action or no action as the director determines in good faith, using reasonable judgment, and discretion.

Communications may be forwarded to all directors if they relate to important substantive matters and include suggestions or comments that may be important for the directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances, and matters as to which we tend to receive repetitive or duplicative communications.

The audit committee oversees the procedures for the receipt, retention, and treatment of complaints received by us regarding accounting, internal accounting controls, or audit matters, and the confidential, anonymous submission by employees of concerns regarding questionable accounting, internal accounting controls or auditing matters. We have also established a toll-free telephone number for the reporting of such activity, which is 866-858-6315.

**Director Compensation**

The table below shows all compensation paid to our non-employee directors during 2018.

<b>Name</b>	<b>Fees Paid In Cash \$(1)</b>	<b>All Other Compensation \$(2)</b>	<b>Option Awards \$(3)</b>	<b>Total (\$)</b>
Andrew R. Allen, M.D., Ph.D.	43,854		138,843	182,697
Kenneth Bate	42,471		138,843	181,314
Carl Goldfischer, M.D.	60,081		138,843	198,924
David M. Mott (4)	103,238		138,843	242,081
Richard F. Pops	42,471		138,843	181,314
Kevin Conroy (5)	51,067		138,843	189,910

Edgar Filing: Epizyme, Inc. - Form DEF 14A

Beth Seidenberg, M.D. (6)	55,060		138,843	193,903
Michael Giordano, M.D. (7)	19,849	416,034	284,055	719,938

- (1) Amounts represent cash compensation for services rendered by each member of the board of directors.
- (2) Amount shown consists of fees paid for consulting and advisory services.
- (3) Amounts shown reflect the grant date fair value of option awards granted during 2018. The grant date fair value was computed in accordance with Financial Accounting Standards Board Accounting Standards, or the FASB, Accounting Standards Codification Topic 718, Compensation - Stock Compensation. See note 10 to the financial statements in our annual report on Form 10-K for the year ended December 31, 2018 regarding assumptions we made in determining the fair value of option awards.

**Table of Contents**

- (4) Includes \$82,500 of fees Mr. Mott elected to receive in common stock in lieu of cash for his 2018 annual board of director fees.
- (5) Includes \$39,000 of fees Mr. Conroy elected to receive in common stock in lieu of cash for his 2018 annual board of director fees.
- (6) Includes \$44,000 of fees Dr. Seidenberg elected to receive in common stock in lieu of cash for her 2018 annual board of director fees.
- (7) Dr. Giordano joined our board of directors in March 2018. Fees paid to Dr. Giordano for his services on our board of directors were pro-rated accordingly.

During 2018, we did not provide any cash compensation to Mr. Bazemore, our President and Chief Executive Officer, for his service as a director. Mr. Bazemore's compensation is set forth under Executive Compensation Summary Compensation Table.

***Director Compensation Program***

Our director compensation program is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our directors' interests with those of our stockholders. Under our director compensation program, we pay our non-employee directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chairman of the board and the chairman of each committee receive additional retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment is prorated for any portion of such quarter that the director is not serving on our board of directors.

In 2018, directors received the following cash fees under our director compensation program for service on the board of directors, as chairman of our board of directors and for service on each committee of the board of directors on which the director is a member.

	<b>Member Annual Fee</b>	<b>Chairman Additional Annual Fee</b>
Board of Directors	\$ 35,000	\$ 35,000
Audit Committee	7,500	7,500
Compensation Committee	5,000	7,500
Nominating and Corporate Governance Committee	4,000	4,500

Under the director compensation program, directors have the right to elect to receive 100% of their cash fees payable in a calendar year in the form of unrestricted shares of our common stock in lieu of cash fees. These shares of common stock are issued under our 2013 Stock Incentive Plan, or the 2013 Plan. Shares of our common stock issued in lieu of director fees are issued on the date of the annual meeting, and the number of shares to be issued to participating directors is determined by dividing the expected cash fees to be paid for the full year by the closing price of the Company's common stock on the day of the annual meeting. Each incumbent director may elect to receive stock for fees prior to the beginning of each fiscal year, and each new director has the immediate option to elect to receive stock for fees, beginning with the next full fiscal year during which he or she serves. In 2018, three members of the Board, Beth Seidenberg, David Mott and Kevin Conroy, elected to receive their cash fees in the form of unrestricted shares of our common stock.

In addition, in January 2019 our compensation committee, in consultation with Pearl Meyer, recommended for approval by our board of directors, and our board of directors approved, updates to our director compensation

program. Under our updated director compensation program, upon a non-employee director's initial election to our board of directors, such director will receive an option to purchase the number of shares of our common stock that have a Black-Scholes value as of the date of grant equal to \$300,000 (as calculated using the same methodology that we use to calculate the value of stock awards for purposes of our financial statements);



**Table of Contents**

however, the number of shares of common stock issuable upon such option may in no event exceed 50,000 shares. On the date of each annual meeting of stockholders, each non-employee director that has served on our board of directors for at least six months and that continues to serve on our board of directors after such annual meeting, will receive an option to purchase the number of shares of our common stock that have a Black-Scholes value as of the date of grant equal to \$150,000 (as calculated using the same methodology that we use to calculate the value of stock awards for purposes of our financial statements); however, in no year may the number of shares of common stock issuable upon such option exceed 25,000 shares. Subject to the non-employee director's continued service as a director, each option will vest with respect to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal monthly installments thereafter until the fourth anniversary of the grant date. Under the updated director compensation plan, we also agreed to pay the following annual cash fees to our non-employee directors as consideration for their service on our board:

	<b>Member Annual Fee</b>	<b>Chairman Additional Annual Fee</b>
Board of Directors	\$ 40,000	\$ 35,000
Audit Committee	7,500	15,000
Compensation Committee	6,250	12,500
Nominating and Corporate Governance Committee	4,500	9,000

**Table of Contents****EXECUTIVE COMPENSATION*****Compensation Discussion and Analysis*****Overview**

Our compensation committee is responsible for reviewing and approving, or recommending for approval by the board of directors, the compensation of our named executive officers, including salary, cash bonus and equity incentive compensation levels, severance arrangements, change in control benefits and other forms of compensation. This section discusses the philosophy, programs, processes, decisions, and other relevant information with respect to the compensation of our named executive officers, or NEOs.

Our NEOs for the year ended December 31, 2018 were:

<b>Name</b>	<b>Title</b>
Robert Bazemore	President and Chief Executive Officer
Matthew Ros	Chief Strategy and Business Officer
Shefali Agarwal	Chief Medical Officer
Susan Graf	(former) Chief Business Officer
Suzanne Fleming	(former) Senior Vice President of Finance and Treasurer

Ms. Graf served as our Chief Business Officer until September 2018. Ms. Fleming served as our Senior Vice President of Finance and Treasurer until January 2019.

***Our Vision & Mission***

Our vision is to rewrite therapy for cancer and other serious diseases through targeted epigenetic medicines. We aspire to change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action. We are focused on creating medicines that are targeted at specific causes of diseases, that are

orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them. Since 2011, we have discovered five novel epigenetic therapies, three of which are in clinical development and two that have begun or will soon begin IND-enabling studies.

Our team is wholly dedicated to bringing epigenetic therapies to the many patients who can potentially benefit from them. We believe that we have the opportunity to change the lives of patients living with cancer and other serious diseases.

### *Business Environment and Performance*

As a late-stage biotechnology company headquartered in Cambridge, Massachusetts, we operate in a highly competitive environment for capital and talent. Achieving our mission requires vision, expertise and execution from our executives. 2018 was a year of tremendous progress towards our long-term goals and mission, highlighted by the following:

#### Scientific / Pipeline

Identified registration path for tazemetostat clinical trials in EZH2 wild type and mutant follicular lymphoma

Successfully resolved partial clinical hold in our tazemetostat clinical trials with no major changes to any of our clinical programs or trial populations

**Table of Contents**

Completed enrollment in our Phase 2 trial of tazemetostat in follicular lymphoma

Completed good laboratory practice toxicology work necessary to move EZM8266 into the clinic  
Collaborations

Entered a strategic collaboration with Boehringer Ingelheim focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer

Earned an \$8 million milestone payment from Glaxo Group Limited (an affiliate of GlaxoSmithKline) under our collaboration with Glaxo Group Limited following initiation of patient dosing in a Phase 1 clinical trial of GSK3368715, a first-in-class protein arginine methyltransferase1 (PRMT1) inhibitor discovered by us and the second program to enter the clinic under the collaboration  
Organizational

Appointed Dr. Agarwal as our Chief Medical Officer

Mr. Ros commenced a new role as Chief Strategy and Business Officer

*Key Compensation Decisions and Actions*

Our compensation committee took several actions in 2018 taking into account our compensation philosophy and objectives, the needs and performance of our company, individual performance, and other factors such as market data and industry best practices.

**Base Salary Adjustments.** The compensation committee reviewed base salaries of our NEOs in January 2018. Mr. Bazemore and Mr. Ros each received an annual merit-based salary adjustment reflecting their performance and contributions and to maintain reasonable positioning relative to our peer companies. No adjustments to base salary were made for Ms. Graf or Ms. Fleming. Ms. Graf did not receive a salary adjustment as her base salary had been increased in December 2017 to reflect her assumption of additional responsibilities. The compensation committee determined that Ms. Fleming's salary, which had been set in September 2017 in connection with her hiring, was market competitive. Dr. Agarwal, who joined us in June 2018, was not an employee at the time of the 2018 salary review and her base salary was set at the time of her hire. Further detail relating to salaries paid to our NEOs and the compensation committee's determination of such salaries is provided in the section "Compensation Decisions Annual Base Salary".

**Short-term Incentive Plan Goals and Design.** In January 2018, the compensation committee approved corporate goals and bonus targets for the NEOs as part of our 2018 bonus program. The corporate goals consisted of five corporate objectives, each with its own weighting to reflect their importance to our

business. To the extent goals are partially met or exceeded, the compensation committee may ascribe a partial achievement or overachievement percentage to each goal, as applicable. The compensation committee also reviews individual performance to determine whether the potential bonus should be increased or decreased. In January 2019, the compensation committee reviewed our achievements against our 2018 corporate objectives and agreed to attribute a corporate funding factor of 101.25%. Further detail relating to the Plan is provided in the section Compensation Decisions Short-term Incentives .

**Long-term Incentive Grants.** In January 2018, the compensation committee approved grants of stock options under the 2013 Stock Incentive Plan to our NEOs. The compensation committee also granted stock options under the 2013 Stock Incentive Plan to Dr. Agarwal at the time of her hire. Further detail relating to our long-term incentive grants is provided in the section Compensation Decisions Long-term Incentives.

**Table of Contents**

In January 2019, the compensation committee approved 2019 base salaries, bonus targets for 2019, and new long-term incentive grants. The compensation committee determined that, for 2019, eligible NEOs would receive a 75% of their long-term incentive grant in stock options and 25% in restricted stock units, or RSUs. The compensation committee also approved the grant of performance-based RSUs to our NEOs that contain performance based vesting objectives related largely to our clinical programs for tazemetostat in epithelioid sarcoma and follicular lymphoma. The compensation committee believes that these actions align with our overall compensation philosophy and program objectives.

**Compensation Philosophy and Process**

The goal of our compensation program is to pay for performance. Within this overarching principle, there are a number of key objectives that the compensation program is designed to achieve.

**Overarching Philosophy:**

## Pay for Performance

**Key Objectives:**

Attract and retain qualified executive talent to support our mission, vision, and business objectives	Motivate individuals to achieve our mission, vision, and business objectives	Foster a culture of camaraderie, collaboration, discipline, innovation, openness, patient-focus, and resilience	Align the interests of our NEOs with our stockholders
---	--	---	---

To attract and retain qualified executives, we seek to pay our NEOs compensation that is competitive within our industry. To understand the competitive market for NEO compensation in our industry, we engage our independent compensation consultant, Pearl Meyer, to perform benchmarking exercises. We do not explicitly target a certain percentile from our market benchmarking to compensate our NEOs, but rather review each NEO's positioning relative to the market within the context of his or her experience, contributions, role, potential, and other factors. Similarly, we do not target a specific mix of compensation, although we deliver a majority of compensation through long-term incentives consistent with our pay for performance philosophy, and to be generally competitive with peers in terms of each element of pay.

*Role of the Compensation Committee.* The compensation committee is responsible for establishing and overseeing our executive compensation program. Our compensation committee typically reviews and discusses with our chief executive officer proposed compensation for all executives other than the chief executive officer. Following the compensation committee's discussions with our chief executive officer, and in consideration of the information provided by Pearl Meyer, the compensation committee then consults with the Board about the compensation of each NEO before determining and approving each NEO's compensation for the upcoming fiscal year.

*Role of our Chief Executive Officer.* Our chief executive officer evaluates and reviews with the compensation committee the individual performance and contributions of each of the other NEOs, and makes recommendations to the compensation committee regarding base salary, non-equity incentive plan compensation and equity awards. The

compensation committee reviews and considers such recommendations, but ultimately retains full discretion and authority over the final compensation decisions for the NEOs. Our chief executive officer, in consultation with other members of our management team, also recommends the Company performance objectives that are used to determine bonus amounts.

*Role of our Independent Compensation Consultant.* Pursuant to its charter, the compensation committee has the sole authority to retain compensation consultants to assist in its evaluation of executive and director compensation. Our compensation committee engaged Pearl Meyer as its independent compensation consultant to

**Table of Contents**

review our executive compensation peer group and program design and assess our executives' compensation relative to comparable companies. Pearl Meyer provides our compensation committee with information regarding market compensation practices and trends. Our compensation committee considered the relationship that Pearl Meyer has with us, the members of our board of directors and our executive officers, and has determined that Pearl Meyer is serving, and has served, as an independent and conflict-free advisor to the compensation committee.

*Factors in Setting Compensation*

The compensation committee reviews NEO compensation annually. As part of its annual compensation review, the compensation committee evaluates our compensation program and arrangements for our NEOs based on a number of factors, including:

**Internal Factors**

Compensation philosophy and objectives

Company goals and objectives

Historical company performance and company outlook

Individual NEO roles and profiles

Individual performance and contributions

Current and historical pay data for NEOs

**External Factors**

Peer group information and data

Broader industry specific information and data

Compensation committee experience

Market dynamics

An important external factor in making compensation decisions is our compensation peer group. The compensation committee considers a select number of key inputs, summarized below, to determine the companies to be included in the peer group. The compensation data from the peer group provide a benchmark for market-competitive base salaries, short- and long-term incentive targets, and estimated total direct compensation. In certain cases where the peer group data is limited for a particular role, Pearl Meyer provides us with a blend of peer data and survey data where it concludes the peer data is not conclusive. This data provides context for the committee in setting targeted pay levels going forward.

In September 2017, the compensation committee, together with Pearl Meyer, used the following screening criteria to determine a recommended group of companies to be in the peer group to be used in setting 2018 compensation:

**Criteria**

Industry  
Development Stage

**Description**

U.S. publicly-traded biotechnology or pharmaceutical companies  
Companies with a lead asset in phase II or III trials



## Edgar Filing: Epizyme, Inc. - Form DEF 14A

Size 1/3x to 3x that of Epizyme for market capitalization, headcount, and R&D expenses

Other Companies with an oncology focus

Based on this screening criteria, in September 2017 the compensation committee approved a peer group of 20 companies, listed below.

Acceleron Pharma Inc.  
Aduro BioTech, Inc.  
Agius Pharmaceuticals, Inc.  
Akebia Therapeutics, Inc.  
Array BioPharma Inc.  
bluebird bio, Inc.  
Blueprint Medicines Corp.

Celldex Therapeutics, Inc.  
Clovis Oncology, Inc.  
Dynavax Technologies Corporation  
Five Prime Therapeutics, Inc.  
Ignyta, Inc.  
Inovio Pharmaceuticals, Inc.  
Juno Therapeutics, Inc.

Karyopharm Therapeutics Inc.  
MacroGenics, Inc  
OncoMed Pharmaceuticals, Inc.  
Seres Therapeutics, Inc.  
Xencor, Inc.  
ZIOPHARM Oncology, Inc.

**Table of Contents**

The summary statistics below demonstrate how we compared to the companies in the peer group in September 2017.

<b>Statistic</b>	<b>Market Capitalization</b>	<b>Headcount</b>	<b>R&amp;D Expense</b>
	<b>(\$B)</b>		<b>(\$M)</b>
75 <sup>th</sup> Percentile	\$1.8	258	\$171
50 <sup>th</sup> Percentile	\$0.9	177	\$100
25 <sup>th</sup> Percentile	\$0.6	108	\$84
<b>Epizyme</b>	<b>\$1.0</b>	<b>112</b>	<b>\$108</b>

In October 2018, the compensation committee, with the assistance of Pearl Meyer, reviewed the companies included in the 2018 peer group for continued appropriateness in 2019 using the same criteria it used to determine the 2018 peer group. Pearl Meyer recommended the following changes to the peer group, which the compensation committee approved. This group was used to set compensation for fiscal year 2019.

<b>Action</b>	<b>Company</b>	<b>Rationale</b>
Companies recommended for exclusion from the current group	Agios Pharmaceuticals, Inc.	Market capitalization above range
	bluebird bio, Inc.	Market capitalization above range
	Celldex Therapeutics, Inc.	Market capitalization below range
	Ignyta, Inc.	Acquired
	Juno Therapeutics, Inc.	Acquired
	OncoMed Pharmaceuticals, Inc.	Market capitalization below range
Companies recommended for inclusion in the 2019 peer group	Deciphera Pharmaceuticals, Inc.	Met screening criteria
	ImmunoGen, Inc.	Met screening criteria
	Iovance Biotherapeutics, Inc.	Met screening criteria
	Mirati Therapeutics, Inc.	Met screening criteria
	Odonate Therapeutics, Inc.	Met screening criteria
	Syros Pharmaceuticals, Inc.	Met screening criteria

**Compensation Elements and Decisions**

The primary elements of our executive compensation program are:

<b>Element</b>	<b>Purpose</b>	<b>Timing</b>
Base Salary	Fixed amount to attract and retain top talent.	Initial base salaries are set at the time of hire, and adjustments to base salaries are considered in conjunction with

changes in job responsibility or annually as part of our merit increase process.

**Table of Contents**

<b>Element</b>	<b>Purpose</b>	<b>Timing</b>
Short-term Incentives	Performance-contingent compensation to reward company and individual performance against a set of annual goals.	Generally measured and paid out on an annual basis, typically in the first quarter of the following fiscal year.
Long-term Incentives	Variable incentive compensation to promote performance, support retention, and create stockholder alignment.	Generally granted at the time of hire, and annually following the close of the previous fiscal year.
Severance and Change in Control Benefits	Competitive benefits consistent with industry practice	Upon a change of control of our company or an NEOs termination of employment
Benefits	Fixed benefits to promote individual health, welfare and financial security.	The timing of our benefits varies by element.

**Annual Base Salary.**

Base salaries are used to recognize the experience, skills, knowledge and responsibilities required of our NEOs. Base salaries for our NEOs are established at the time the NEO is hired, taking into account the position for which the NEO is being considered and the NEOs qualifications, prior experience and prior salary. None of our NEOs is currently party to an employment agreement that provides for automatic or scheduled increases in base salary. However, on an annual basis, our compensation committee reviews and evaluates, with input from our chief executive officer (other than with respect to himself), the need for adjustment of the base salaries of our NEOs based on changes and expected changes in the scope of a NEOs responsibilities, including promotions, the individual contributions made by and performance of the NEO during the prior year, overall labor market conditions, the relative ease or difficulty of replacing the executive with a well-qualified person, our overall growth and development as a company and general salary trends in our industry and among our peer group and where the NEOs salary falls in the salary range presented by that data. In making decisions regarding salary increases, our compensation committee may also draw upon the experience of members of the committee with other companies. No formulaic base salary increases are provided to our NEOs.

The following table presents the base salaries for each of our NEOs for the years 2017 and 2018, as approved by our compensation committee. The 2017 base salaries became effective on January 1, 2017. The 2018 base salaries became effective on January 1, 2018.

<b>Named Executive</b>	<b>2017</b>	<b>January 2018 Adjustment</b>		<b>2018</b>	<b>Nature of Increase</b>
	<b>Annualized Salary</b>	<b>% of Base Salary</b>	<b>Amount</b>	<b>Annualized Salary</b>	
<b>Officer</b>	<b>(\$)</b>		<b>(\$)</b>	<b>(\$)</b>	
Robert Bazemore	556,200	3.5%	19,467	575,667	Merit increase
Matthew Ros	391,400	7.3%	28,600	420,000	Merit increase

			and market adjustment Set at time of hire
Shefali Agarwal (1)		450,000	
Susan Graf (2)	415,000	415,000	
Suzanne Fleming (3)	350,000	350,000	

**Table of Contents**

- (1) Dr. Agarwal was hired in June 2018 and was not part of the January 2018 merit increase process.
- (2) Ms. Graf's base salary was adjusted in December 2017 to reflect additional responsibilities taken at that time.
- (3) Ms. Fleming was hired in September 2017 and her base salary for 2018 was fixed at that time.
- Short-term Incentives.** Our bonus program is designed to motivate and reward our NEOs for achievements relative to our goals and expectations for each fiscal year. Under our bonus program, each NEO has a target bonus opportunity, defined as a percentage of his or her annual base salary. The general design of our bonus program is as follows:

$$\text{NEO Base Salary} \times \text{NEO Target Bonus} \times \text{Corporate Funding Factor} \times \text{Individual Performance Modifier} = \text{Short-term Incentive Earned}$$

In January 2018, our compensation committee set the following target bonus opportunities for each NEO:

NEO	2018 Base Salary (\$)	Target Bonus %	Target Bonus Award (\$)
Robert Bazemore	575,667	55%	316,617
Matthew Ros	420,000	40%	168,000
Shefali Agarwal (1)	450,000	40%	180,000
Susan Graf	415,000	40%	166,000
Suzanne Fleming	350,000	35%	122,500

- (1) Dr. Agarwal's 2018 target bonus was established at the time of her hire. Our compensation committee then established the following corporate objectives to assess our corporate performance in 2018. In January 2019, the compensation committee reviewed our achievements against these corporate goals to arrive at a corporate funding factor of 101.25%.

Goal /Assessment	Weighting
1. <b>Goal:</b> Develop and execute against an expeditious follicular lymphoma, or FL, registration path, in consultation with the Food and Drug Administration, or FDA, to support submission of an FL New Drug	40%

Application, or NDA, in 2019

**Assessment:**

Successful end-of-Phase 2 meeting with FDA

FL enrollment completed in 4Q

FL natural history assessment completed supports intended registration strategy

Prepare to initiate FL combo studies in 2019

2. **Goal:** Submit epithelioid sarcoma, or ES, NDA in the US (4Q) 30%

**Assessment:**

ES NDA intentionally delayed until 2Q 2019

ES natural history study completed plan to explore with FDA seeking approval without Phase 3 requirement

Mock inspections initiated, and on track

Supply chain secured / positive chemistry manufacturing and controls meeting with FDA

**Table of Contents**

	<b>Goal /Assessment</b>	<b>Weighting</b>
3.	<p><b>Goal:</b> Develop board of directors-approved go-to-market strategic options for tazemetostat (3Q)</p> <p><b>Assessment:</b></p> <p style="padding-left: 40px;">Exploring tazemetostat partnering opportunities to maximize asset value</p> <p style="padding-left: 40px;">Operational launch plan developed for ES, and commercial lead hired</p>	15%
4.	<p><b>Goal:</b> Complete all US investigational new drug application, or IND, and Canadian clinical trial application enabling work for G9a and file IND by year end (4Q)</p> <p><b>Assessment:</b></p> <p style="padding-left: 40px;">IND-enabling good laboratory practice toxicology studies concluded</p> <p style="padding-left: 40px;">First-in-Human clinical program designed</p> <p style="padding-left: 40px;">Pre-IND meeting to be scheduled in 2Q</p>	10%
5.	<p><b>Goal:</b> Goals related to organizational effectiveness, financial rigor and compliance</p> <p><b>Assessment:</b></p> <p style="padding-left: 40px;">Boehringer Ingelheim deal executed;</p> <p style="padding-left: 40px;">Financing in October extends cash runway</p> <p style="padding-left: 40px;">Chief Medical Officer hired, and key clinical roles have been filled</p> <p style="padding-left: 40px;">Satellite site closed, and 10 full time employees eliminated</p>	5%
	<b>Total</b>	<b>100%</b>

*Individual Performance Considerations*

Our compensation committee also evaluates the individual performance of our NEOs. Consistent with this process, our compensation committee assessed the performance of our chief executive officer in 2018 based on our relative achievement of our corporate goals as well as his leadership in driving the execution of our strategic plans. In assessing the individual performance in 2018 of our NEOs other than our chief executive officer, our compensation committee, with the input of our chief executive officer, considered each such officer's individual contributions to the completion of our goals, and the officer's individual achievements in helping to build the company and execute on our



strategy. These achievements include the following:

*Robert Bazemore, President & CEO:* Mr. Bazemore's short term incentive payment is based 100% upon the achievement of the Company-wide annual goals. Accordingly, for 2018, Mr. Bazemore earned 101.25% of his total target short term incentive payment.

*Matthew Ros, Chief Strategy & Business Officer:* Mr. Ros was assigned objectives related to (1) providing leadership and continuing to build the organization, (2) successfully concluding the Boehringer Ingelheim collaboration, (3) achieving financial goals related to capital raising activities, (4) exploring tazemetostat partnering opportunities to maximize asset value, and (5) developing the strategic and operational launch plan for tazemetostat in epithelioid sarcoma, as well as hiring a senior vice president to lead the commercial function. Given his exceptional leadership contributions along with taking on additional scope of responsibilities throughout 2018, the Compensation Committee determined Mr. Ros achieved 110% related to his individual objectives.

*Shefali Agarwal, Chief Medical Officer:* Dr. Agarwal was assigned objectives related to (1) providing leadership and continuing to build the clinical organization, (2) supporting various regulatory objectives

**Table of Contents**

including development of a registration path in follicular lymphoma (including a successful EOP2 meeting with the FDA and completion of study enrollment), and progression of the NDA in epithelioid sarcoma, and (3) progressing our clinical programs related to the further development of tazemetostat. Given her exceptional results in these areas in her first year of employment, in addition to her key role in the successful resolution of the partial clinical hold on Tazemetostat, the Compensation Committee determined that Dr. Agarwal achieved 110% related to her individual objectives.

*Susan Graf, (former) Chief Business Officer:* Ms. Graf was assigned objectives related to (1) progressing the Boehringer Ingelheim collaboration, (2) achieving financial goals related to capital raising activities, and (3) exploring tazemetostat partnering opportunities to maximize asset value. The Compensation Committee determined that prior to her departure from the company in 2018, Ms. Graf achieved 90% related to her individual objectives, which was paid on a prorated basis.

*Final Calculations*

The final calculations used to arrive at the 2018 bonus awards are as follows:

NEO	2018 Base Salary (\$)	X	Target Bonus %	X	Corporate Funding Factor	X	Individual Performance Modifier	=	Bonus Award (\$)
Robert Bazemore	575,667	X	55%	X	101.25%	X	100%	=	<b>320,575</b>
Matthew Ros	420,000	X	40%	X	101.25%	X	110%	=	<b>187,100</b>
Shefali Agarwal (1)	450,000	X	40%	X	101.25%	X	110%	=	<b>200,500</b>
Susan Graf (2)	311,250	X	40%	X	92.50%	X	90%	=	<b>103,646</b>
Suzanne Fleming (3)	350,000	X	35%	X		X		=	<b>0</b>

- (1) Dr. Agarwal's 2018 bonus award represents the full year bonus per her offer letter.
- (2) Ms. Graf departed Epizyme in September 2018. Her base salary is pro-rated for service time to arrive at her award.
- (3) Ms. Fleming departed Epizyme in January 2019.

In addition to these short-term incentive payouts, the compensation committee may approve cash bonuses to induce individuals to join our company or make up for lost compensation opportunities at previous employers, commonly referred to as sign-on bonuses. In 2017, the compensation committee approved a sign-on bonus for Ms. Fleming. The sign-on bonus was structured to include an initial payment of \$75,000 in 2017 and payments of \$50,000 on each of March 1, 2018 and September 1, 2018. Dr. Agarwal received a \$125,000 sign-on bonus upon joining the company in June 2018.

**Long-term incentives.**

Long-term incentives represent a key component to our overall compensation program, and in many cases represent the majority of total annual compensation.

We believe that equity grants provide our NEOs with a strong link to our long-term performance, create an ownership culture and help to align the interests of our NEOs and our stockholders. Our NEOs benefit from equity awards as our stock price increases through the creation of shareholder value. Accordingly, we believe equity awards provide

meaningful incentives to our NEOs to achieve increases in the value of our stock over time. In addition, the vesting feature of our equity awards contributes to NEO retention by providing an incentive to our NEOs to remain employed by us during the vesting period.

The compensation committee typically approves stock option grants for NEOs at the start of their employment, and annually thereafter in connection with the annual performance review. Additionally, the compensation

**Table of Contents**

committee may periodically grant additional equity awards based on individual role, performance and contribution, as well as competitive market data and information.

None of our NEOs are currently party to an employment agreement that provides for an automatic award of stock options. We grant equity awards to our NEOs with time-based vesting. The stock options that we grant to our NEOs typically become exercisable as to 25% of the shares underlying the option on the first anniversary of the grant date, and as to an additional 1/36th of the shares underlying the option monthly thereafter. The exercise price of all stock options equals the fair market value of shares of our common stock on the date of grant. Prior to the exercise of an option, the holder has no rights as a stockholder with respect to the shares subject to such option, including no voting rights and no right to receive dividends or dividend equivalents. Vesting and exercise rights for stock options cease shortly after termination of employment except in the case of death or disability. In specified termination and change in control circumstances, equity awards held by our NEOs are subject to accelerated vesting. See Severance and Change in Control Benefits for further information.

In determining long-term incentive grants for new hires, the compensation committee evaluates (where available):

market data for annual and new hire long-term incentive grant values;

potential lost long-term incentive opportunity from candidate's current employer, where available; and

candidate background, experience, and potential.

In determining annual long-term incentive grants for existing NEOs, the committee reviews:

market data for annual long-term incentive grant values;

time the NEO has been employed with us;

NEO performance and contributions in the previous year;

overall corporate performance and outlook; and

NEO current outstanding equity, including the value of outstanding unvested awards.

In February 2018, our compensation committee approved the grant of stock options under our 2013 Plan to each of our NEOs other than Dr. Agarwal. Each of these equity awards had an exercise price equal to the fair market value of our common stock on the date of grant and vests with respect to 25% of the shares on February 9, 2019 and with respect to the remaining shares in approximately equal monthly installments over the following three years.

The following table sets forth the number of shares of common stock issuable upon exercise of the stock options granted to our NEOs in February 2018:

NEO	Compensation Committee Approved Fair Value (1)	Number of Shares
		Underlying Options (#)
Robert Bazemore	\$2,750,000	265,860
Matthew Ros	\$1,100,000	106,344
Shefali Agarwal (2)		
Susan Graf	\$1,100,000	106,344
Suzanne Fleming	\$300,000	29,002

---

**Table of Contents**

- (1) These figures may be different than those reported in the Summary Compensation Table and other required tabular disclosures due to the process of converting a fair value to a number of stock options and associated rounding.
- (2) Dr. Agarwal was hired in June 2018 and was not part of the February 2018 long-term incentive award process. In addition to these grants, the compensation committee granted stock options to purchase 170,000 shares of our common stock to Dr. Agarwal at the time of her hire, representing approximately \$1,500,000 in grant date fair value. These stock options have the same vesting schedule as the February 2018 grants to the other NEOs.

***Severance and Change of Control Benefits***

Each NEO is also eligible for severance benefits in specified circumstances, as set forth in our Executive Severance and Change in Control Plan, as amended. Under the terms of this plan, upon execution and effectiveness of a severance agreement and release of claims, each named executive officer will be entitled to severance payments if we:

terminate his or her employment without cause, prior to or more than 12 months following a change in control; or

terminate his or her employment without cause or he or she terminates employment with us for good reason within 12 months following a change in control.

Additionally, Mr. Bazemore is entitled to severance payments if he terminates his employment with us for good reason prior to or more than 12 months following a change in control. Please refer to [Employment, Severance and Change in Control Arrangements](#) below for a more detailed discussion of severance and change in control benefits for our named executive officers.

***Benefits.***

We generally pay relocation expenses for newly-hired NEOs whom we require to relocate as a condition to their employment with us. We also have, and may in the future, pay local housing expenses and travel costs for executives who maintain a primary residence outside of a reasonable daily commuting range to our headquarters prior to such executive's relocation. We evaluate the competitiveness of our arrangements periodically and have found that our NEO benefits are competitive with our peers. For more information on our employment arrangements, please see

[Employment, Severance and Change in Control Arrangements](#). We believe that these are typical benefits offered by comparable companies to executives who are asked to relocate and that we would be at a competitive disadvantage in trying to attract executives who would need to relocate in order to work for us if we did not offer such assistance.

We maintain a defined contribution employee retirement plan for our employees. Our 401(k) plan is intended to qualify as a tax-qualified plan under Section 401 of the Internal Revenue Code so that contributions to our 401(k) plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k) plan. Our 401(k) plan provides that each participant may contribute up to 90% of his or her pre-tax compensation, up to a statutory limit, which was \$18,500 for 2018. Participants who are at least 50 years old can also make catch-up contributions, which in 2018 could be up to an additional \$6,000 above the statutory limit. Under our 401(k) plan, each employee is fully vested in his or her deferred salary contributions. Employee contributions are held and invested by the plan's trustee, subject to participants' ability to give investment directions by following certain procedures. During the year ended December 31, 2018, we provided a matching contribution to the 401(k) plan, matching 50% of an employee's contribution up to a maximum of 3% of the participant's compensation. Matching contributions made to each of our named executive officers are included in the [Summary Compensation Table](#). All

Other Compensation.

## **Table of Contents**

Our NEOs are eligible to participate in all of our employee benefit plans, including our medical, dental, long-term disability and term life insurance plans, our fitness benefits and 401(k) matching contributions, in each case on the same basis as other employees. We do not provide additional perquisites or personal benefits to our NEOs. We do not sponsor any qualified or non-qualified defined benefit plans for any of our employees, including NEOs.

## **Other**

### ***Anti-Hedging and Pledging Policy***

Our insider trading policy expressly prohibits all of our employees, including our NEOs, as well as our directors, from engaging in speculative transactions in our stock, including short sales, puts/calls, hedging transactions and margin accounts or pledges.

### ***No Tax Gross-ups***

We do not provide for any tax gross-up payments to our NEOs.

### ***Tax and Accounting Considerations***

Under Section 162(m) of the Internal Revenue Code of 1986, as amended, a company will generally not be entitled to a tax deduction for individual compensation over \$1 million that is paid to certain executive officers. As in effect prior to its recent amendment by the Tax Cuts and Jobs Act of 2017, Section 162(m) provided an exception to the deductibility limitations for performance-based compensation that met certain requirements. While considering the impact of Section 162(m) and awarding certain elements of compensation that, at the time, were intended to qualify as performance-based compensation, the compensation committee did not adopt a policy requiring all compensation to be fully deductible under Section 162(m). As Section 162(m) has been amended, effective for taxable years beginning after December 31, 2017, the performance-based compensation exception was eliminated from Section 162(m), except for certain grandfathered arrangements under the transition rules. In light of this amendment, the Committee will continue to consider the potential impact of the application of Section 162(m) on compensation for our executive officers and reserves the right to provide compensation to executive officers that may not be tax-deductible, as well as the right to modify compensation that was initially intended to qualify as performance-based compensation if it believes that taking any such action is in the best interests of our company and stockholders.

### ***Compensation Risk Assessment***

Our management and the compensation committee review our compensation practices and policies with regard to risk management. We have reviewed our programs and determined that there are no practices or policies that are likely to lead to excessive risk-taking or have a material adverse effect on the Company. Further, we identified the following practices that serve to mitigate risk:

we provide a balance of fixed and performance-based compensation;

our short-term incentive plan is based on a number of challenging goals;



our long-term incentive grants vest over time, generally four years;

our compensation committee has discretion to reduce bonus awards should the objective formula yield an inappropriate result;

we have an independent compensation committee;

we engage with independent compensation advisors;

we have proper administrative and oversight controls; and

we have an established compensation committee calendar for governance purposes.

**Table of Contents****Compensation Committee Report**

The compensation committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with our management. Based on this review and discussion, the compensation committee recommended to the board of directors that the Compensation Discussion and Analysis be included in this proxy statement.

THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF EPIZYME, INC.

David M. Mott, Chairman

Andrew R. Allen, M.D., Ph.D.

Beth Seidenberg, M.D.

**Summary Compensation Table**

The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for the years ended December 31, 2018, 2017 and 2016.

Name and Principal Position	Year	Salary (\$)	Non-equity Stock Incentive plan			All Other Compensation (\$)(4)	Total
			Bonus Awards (\$)(1)	Option Awards (\$)(2)	Option Awards (\$)(3)		
Robert B. Bazemore Jr. President and Chief Executive Officer	2018	575,667		320,575	2,748,939	5,690	3,650,871
	2017	556,200		282,967	2,748,879	5,603	3,593,649
	2016	540,000		245,700	2,507,753	5,320	3,298,773
Susan E. Graf (5) Former Chief Business Officer	2018	328,009(7)		103,646	1,099,576	114,654	1,645,885
	2017	388,967		153,550	899,627	11,149	1,453,293
Suzanne Fleming (6) Former Senior Vice President, Finance and Treasurer	2018	350,000	100,000		299,875	13,580	763,455
Matthew E. Ros Chief Strategy and Business Officer	2018	420,000		187,100	1,099,576	12,214	1,718,890
	2017	391,400		159,300	899,627	5,666	1,455,993
	2016	237,500	65,000	86,864	1,128,422	2,837	1,520,623
Dr. Shefali Agarwal Chief Medical Officer	2018	199,615	125,000	200,500	1,472,846	1,648	1,999,609

(1) The 2017 and 2018 amounts reflect one-time sign-on bonuses paid pursuant to the terms of the named executive officer's employment agreement.

(2)

## Edgar Filing: Epizyme, Inc. - Form DEF 14A

The amounts reflect the grant date fair value for awards granted during the applicable year. The grant date fair value was computed in accordance with FASB Codification Topic 718, Compensation - Stock Compensation. See note 10 to the financial statements in our annual report on Form 10-K for the year ended December 31, 2018 regarding assumptions we made in determining the fair value of option awards.

- (3) The amounts reflect the annual performance bonuses paid, as discussed under Compensation Discussion and Analysis Annual Base Salary Short-term Incentives.
- (4) All other compensation includes the following for the year ended December 31, 2018:

**Table of Contents**

Name	Gym (\$)	Post Separation Benefits (\$)	401(K) Employer Match (\$)	Transportation Benefits (\$)	Short-term and Long-term Life Insurance Disability Premiums
					(\$)
Robert B. Bazemore	360			3,900	1,430
Susan E. Graf		103,750	6,256	3,575	1,073
Suzanne Fleming			8,250	3,900	1,430
Matthew Ros			6,884	3,900	1,430
Shefali Agarwal				1,052	596

(5) Susan E. Graf departed Epizyme in September 2018.

(6) Suzanne Fleming departed Epizyme in January 2019.

(7) Includes a payment of \$8,379 for accrued and unused vacation time.

**Grants of Plan-Based Awards Table**

The following table sets forth information concerning each grant of an award made to our named executive officer during the fiscal year ended December 31, 2018 under any plan, contract, authorization or arrangement pursuant to which cash, securities, similar instruments or other property may be received.

Name	Grant Date	All other option Number of securities underlying options (#)	Exercise or base price of option awards (\$)	Grant date fair value of stock and option awards \$(1)
Robert B. Bazemore (2)	2/9/2018	265,860	16.00	2,748,939
Susan E. Graf (3)	2/9/2018	106,344	16.00	1,099,576
Suzanne Fleming (4)	2/9/2018	29,002	16.00	299,875
Matthew Ros (2)	2/9/2018	106,344	16.00	1,099,576
Shefali Agarwal (2)	7/23/2018	170,000	13.35	1,472,846

(1) The amounts reflect the grant date fair value for awards granted during the applicable year. The grant date fair value was computed in accordance with FASB Codification Topic 718, Compensation Stock Compensation. See note 10 to the financial statements in our annual report on Form 10-K for the year ended December 31, 2018 regarding assumptions we made in determining the fair value of option awards.

(2) For information on vesting acceleration upon termination of employment, see the Employment, Severance and Change in Control Arrangements section below.

(3) None of the awards granted to Ms. Graf during the fiscal year ended December 31, 2018 had vested as of her departure in September 2018. Ms. Graf forfeited these option awards upon her departure.

(4)

None of the awards granted to Ms. Fleming during the fiscal year ended December 31, 2018 had vested as of her departure in January 2019. Ms. Fleming forfeited these option awards upon her departure.

**Table of Contents****Outstanding Equity Awards at 2018 Fiscal Year End Table**

The following table presents information regarding all outstanding stock options held by each of our named executive officers on December 31, 2018.

Name	Grant Date	Notes	Option Awards				
			Number of Securities		Option Exercise Price (\$)	Option Expiration Date	
			Unexercised Options Exercisable (#)	Underlying Unexercisable Options (#)			
Robert B. Bazemore	8/5/2015	(1)	250,000	50,000	22.29	8/4/2025	
	2/8/2016	(2)	292,187	120,313	8.98	2/7/2026	
	2/8/2017	(3)	153,864	181,840	12.45	2/7/2027	
	2/9/2018	(4)		265,860	16.00	2/8/2028	
Susan E. Graf(9)	4/25/2016	(5)			12.12	4/24/2026	
	2/8/2017	(3)			12.45	2/7/2027	
	2/9/2018	(4)			16.00	2/8/2028	
Suzanne Fleming	9/20/17	(6)	28,181	61,999	18.70	9/19/2027	
	2/9/2018	(4)		29,002	16.00	2/8/2028	
Matthew Ros	5/16/2016	(7)	39,748	61,426	9.58	5/15/2026	
	2/8/2017	(3)	50,355	59,511	12.45	2/7/2027	
	2/9/2018	(4)		106,344	16.00	2/8/2028	
Shefali Agarwal	7/23/2018	(8)		170,000	13.35	7/22/2028	

- (1) The shares under this option vested as to 25% of the unvested shares on August 5, 2016, with the remainder vesting in approximately equal monthly installments through August 5, 2019.
- (2) The shares under this option vested as to 25% of the unvested shares on February 8, 2017, with the remainder vesting in approximately equal monthly installments through February 8, 2020.
- (3) The shares under this option vested as to 25% of the unvested shares on February 8, 2018, with the remainder vesting in approximately equal monthly installments through February 8, 2021.
- (4) The shares under this option vested as to 25% of the unvested shares on February 9, 2019, with the remainder vesting in approximately equal monthly installments through February 9, 2022.
- (5) The shares under this option vested as to 25% of the unvested shares on April 25, 2017, with the remainder vesting in approximately equal monthly installments through April 25, 2020.
- (6) The shares under this option vested as to 25% of the unvested shares on September 20, 2018, with the remainder vesting in approximately equal monthly installments through September 20, 2021.
- (7) The shares under this option vested as to 25% of the unvested shares on May 16, 2017, with the remainder vesting in approximately equal monthly installments through May 16, 2020.
- (8) The shares under this option vested as to 25% of the unvested shares on July 23, 2019, with the remainder vesting in approximately equal monthly installments through July 23, 2022.
- (9) Susan E. Graf's options expired 90 days following her departure from Epizyme in September 2018.

**Option Exercises and Stock Vested**

The following table sets forth information concerning option exercises and stock vested for each of our named executive officers during the fiscal year ended December 31, 2018:

	<b>Option Awards</b>	<b>Value Realized</b>
	<b>Number of Shares</b>	<b>on Exercise</b>
	<b>Acquired on Exercise (#)</b>	<b>(\$)</b>
Robert B. Bazemore		
Susan E. Graf		
Suzanne Fleming		
Matthew Ros	72,264	1,201,693
Shefali Agarwal		

**Table of Contents**

***Employment, Severance and Change in Control Arrangements***

*Robert Bazemore.* We entered into an employment offer letter with Mr. Bazemore, our president and chief executive officer, on August 5, 2015. The employment offer letter established the terms of his employment with us, including his title, salary, bonus and eligibility for benefits. Pursuant to the employment offer letter, on August 5, 2015, the Company granted to Mr. Bazemore stock options to purchase 300,000 shares of common stock of the Company. This award is subject to time-based vesting. The employment offer letter also provides that Mr. Bazemore may be eligible for additional equity award grants from time to time.

*Matthew Ros.* We entered into an employment offer letter with Mr. Ros, our chief operating officer, on April 15, 2016. The employment offer letter established the terms of his employment with us, including his title, salary, bonus and eligibility for benefits. Pursuant to the employment offer letter, on April 15, 2016, the Company granted to Mr. Ros stock options to purchase 173,438 shares of common stock of the Company. This award is subject to time-based vesting. The employment offer letter also provides that Mr. Ros may be eligible for additional equity award grants from time to time.

*Shefali Agarwal.* We entered into an employment offer letter with Dr. Agarwal, our chief medical officer on June 18, 2018. The employment offer letter established the terms of her employment with us, including his title, salary, bonus and eligibility for benefits. Pursuant to the employment offer letter, on June 18, 2018, the Company granted to Dr. Agarwal stock options to purchase 170,000 shares of common stock of the Company. This award was subject to time-based vesting. The employment offer letter also provides that Dr. Agarwal may be eligible for additional equity award grants from time to time.

Each of our named executive officers is employed at-will.

Each named executive officer has entered into a non-competition and non-solicitation agreement, which will prohibit him or her from competing with us and soliciting or hiring our employees for a period of one year following the end of his or her employment with us.

Each named executive officer is also eligible for severance benefits in specified circumstances, as set forth in our Executive Severance and Change in Control Plan, as amended. Under the terms of this plan, upon execution and effectiveness of a severance agreement and release of claims, each named executive officer will be entitled to severance payments if we:

terminate his or her employment without cause, prior to or more than 12 months following a change in control; or

terminate his or her employment without cause or he terminates employment with us for good reason within 12 months following a change in control.

Additionally, Mr. Bazemore is entitled to severance payments if he terminates his employment with us for good reason prior to or more than 12 months following a change in control.

The following definitions have been adopted in our Executive Severance and Change in Control Plan under which our named executive officers participate:



cause means (I) with respect to a termination prior to or more than 12 months following a change in control, any of: (a) the executive's conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (b) a good faith finding by us that the executive has (i) engaged in dishonesty, willful misconduct or gross negligence, (ii) breached or threatened to breach the terms of any restrictive covenants or confidentiality agreement or any similar agreement with us, (iii) violated company policies or procedures, or (iv) failed to perform his assigned duties to our satisfaction, following notice of such failure by us and a period of 15 days to cure and (II) with respect to a termination upon or during the 12-month period following a change in control,

---

**Table of Contents**

(i) the executive's conviction of, or plea of guilty or nolo contendere to, any felony; (ii) the willful and continued failure by the executive (other than any such failure resulting from the executive's incapacity due to physical or mental illness) to perform substantially the duties and responsibilities of the executive position after a written demand for substantial performance (providing a period of 15 days to cure) is delivered to the executive by the Company; (iii) the material breach by the executive of the terms of any restrictive covenants or confidentiality agreement with the Company; or (iv) the willful engaging by the executive in fraud or dishonesty which is demonstrably and materially injurious to the Company or its reputation, monetarily or otherwise. No act, or failure to act, on the executive's part shall be deemed willful unless committed or omitted by the executive in bad faith and without reasonable belief that the executive's act or failure to act was in, or not opposed to, the best interest of the Company.

good reason means the occurrence, without the executive's prior written consent, of any of the following events: (i) a material reduction in the executive's authority, duties, or responsibilities; (ii) the relocation of the principal place at which the executive provides services to us by at least 30 miles and to a location such that his daily commuting distance is increased; or (iii) a material reduction of the executive's base salary. No resignation will be treated as a resignation for good reason unless (x) the executive has given written notice to us of his intention to terminate his or her employment for good reason, describing the grounds for such action, no later than 90 days after the first occurrence of such circumstances, (y) the executive has provided us with at least 30 days in which to cure the circumstances, and (z) if we are not successful in curing the circumstances, the executive ends his employment within 30 days following the cure period in (y).

change in control means any of the following:

- (i) the acquisition by an individual, entity or group within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act, referred to as a Person of beneficial ownership of any of our capital stock if, after such acquisition, such Person beneficially owns more than 50% of either (x) our then-outstanding shares of common stock or (y) the combined voting power of our then-outstanding securities entitled to vote generally in the election of directors; provided, however, that any acquisition directly from us will not be a change in control, nor will any acquisition by any individual, entity, or group pursuant to specified business combinations;
- (ii) the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving us or a sale or other disposition of all or substantially all of our assets subject to specified exceptions; or

(iii) the liquidation or dissolution of our company;

provided that, where required to avoid additional taxation under Section 409A, the event that occurs must also be a change in the ownership or effective control of a corporation, or a change in the ownership of a substantial portion of the assets of a corporation as defined under applicable regulations.

**Table of Contents**

The following table summarizes the schedule of severance payments our current named executive officers would receive in the event of a qualifying termination.

<b>Scenario and Executive Level</b>	<b>Salary Continuation</b>	<b>Bonus</b>	<b>Continuation of Employer Portion of Medical, Dental and Vision Benefit Premiums</b>	<b>Acceleration of Unvested Equity</b>
<b>Prior to a Change in Control</b>				
Robert Bazemore	12 months	None	12 months	None
Matthew Ros	9 months	None	9 months	None
Shefali Agarwal	9 months	None	9 months	None
<b>Following a Change in Control</b>				
Robert Bazemore	18 months	150% of target	18 months	100%
Matthew Ros	12 months	100% of target	12 months	100%
Shefali Agarwal	12 months	100% of target	12 months	100%

**Securities Authorized for Issuance Under Equity Compensation Plans****Equity Compensation Plan Information As of December 31, 2018**

<b>Plan Category</b>	<b>(a) Number of Securities to be Issued Upon Exercise of Outstanding Options</b>	<b>(b) Weighted-Average Exercise Price of Outstanding Options</b>	<b>(c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))</b>
Equity compensation plans approved by security holders	5,152,787(1)	\$ 14.48	5,937,859(2)(3)
Equity compensation plans not approved by security holders			
<b>Total</b>	<b>5,152,787</b>	<b>\$ 14.48</b>	<b>5,937,859</b>

- (1) Consists of stock options and restricted stock units issued under our 2008 Stock Incentive Plan, or 2008 Plan, and the 2013 Plan.
- (2) As of December 31, 2018, 11,090,646 shares were available for future issuance under our 2013 Plan, which became effective on June 5, 2013. The number of shares of our common stock reserved for issuance under the 2013 Plan will be increased (i) from time to time by the number of shares of our common stock forfeited upon the expiration, cancellation, forfeiture, cash settlement or other termination of awards under the 2008 Plan, and (ii) annually on the first day of each year, by up to the lesser of (x) 2,500,000 shares of our common stock, (y)

5.0% of the number of shares of our common stock outstanding on the first day of the applicable year and (z) an amount determined by our board of directors. On January 1, 2019, 2,500,000 shares of our common stock were added to the 2013 Plan pursuant to this provision, which shares are not reflected in the number of shares available for issuance under the 2013 Plan.

- (3) As of December 31, 2018, 381,534 shares were available for future issuance under our 2013 Employee Stock Purchase Plan, or 2013 ESPP, which became effective on June 5, 2013. The number of shares of our common stock reserved for issuance under the 2013 ESPP will be increased annually on the first day of each year, by up to the lesser of (x) 233,333 shares of our common stock, (y) 1% of the number of shares of our common stock outstanding on the first day of the applicable year and (z) an amount determined by our board of directors. The board of directors determined not to increase the shares available for issuance under the 2013 ESPP in January 2019.

---

Table of Contents

**Proposal No. 3.**

**ADVISORY VOTE ON EXECUTIVE COMPENSATION**

We are providing our stockholders the opportunity to vote to approve, on an advisory, non-binding basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the SEC's rules. This proposal, which is commonly referred to as "say-on-pay," is required by the recently enacted Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, which added Section 14A to the Exchange Act. Section 14A of the Exchange Act also requires that stockholders have the opportunity to cast an advisory vote with respect to whether future executive compensation advisory votes will be held every one, two or three years, which is the subject of Proposal No. 4.

Our executive compensation programs are designed to attract and retain qualified executive talent to support our mission, vision, and business objectives. These programs embody a pay-for-performance philosophy and reward NEOs for the achievement of our near-term and longer-term financial and strategic goals and for driving corporate financial performance and stability. The programs contain elements of cash and equity-based compensation and are designed to align the interests of our executives with those of our stockholders. We believe our compensation policy strikes an appropriate balance between the implementation of responsible, measured compensation practices and the effective provision of incentives for our NEOs to exert their best efforts for our success. At the same time, we believe our program does not encourage excessive risk-taking by management.

The "Executive Compensation" section of this proxy statement beginning on page 20, including "Compensation Discussion and Analysis," describes in detail our executive compensation programs and the decisions made by the Compensation Committee and the Board of Directors with respect to the year ended December 31, 2018.

Our Board of Directors is asking stockholders to approve a non-binding advisory vote on the following resolution:

RESOLVED, that the compensation paid to the Company's named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation discussion and analysis, the compensation tables and any related material disclosed in this proxy statement, is hereby approved.

As an advisory vote, this proposal is not binding. Neither the outcome of this advisory vote nor of the advisory vote included in Proposal No. 4 overrules any decision by the Company or the Board of Directors (or any committee thereof), creates or implies any change to the fiduciary duties of the Company or the Board of Directors (or any committee thereof), or creates or implies any additional fiduciary duties for the Company or the Board of Directors (or any committee thereof). However, our compensation committee and Board of Directors value the opinions expressed by our stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions for named executive officers.

**The Board of Directors recommends that stockholders vote to approve the compensation of our named executive officers by voting FOR Proposal No. 3.**

Table of Contents

**Proposal No. 4.**

**ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION  
ADVISORY VOTES**

In Proposal No. 3, we are providing our stockholders the opportunity to vote to approve, on an advisory, non-binding basis, the compensation of our named executive officers. In this Proposal No. 4, we are asking our stockholders to cast a non-binding advisory vote regarding the frequency of future executive compensation advisory votes. Stockholders may vote for a frequency of every one, two, or three years, or may abstain.

The Board of Directors will take into consideration the outcome of this vote in making a determination about the frequency of future executive compensation advisory votes. However, because this vote is advisory and non-binding, the Board of Directors may decide that it is in the best interests of our stockholders and the Company to hold the advisory vote to approve executive compensation more or less frequently. In the future, we will propose an advisory vote on the frequency of the executive compensation advisory vote at least once every six calendar years.

After careful consideration, the Board of Directors believes that an executive compensation advisory vote should be held every year, and therefore our Board of Directors recommends that you vote for a frequency of every ONE YEAR for future executive compensation advisory votes.

The Board of Directors believes that an annual executive compensation advisory vote will facilitate more direct stockholder input about executive compensation. An annual executive compensation advisory vote is consistent with our policy of reviewing our compensation program annually, as well as seeking frequent input from our stockholders on corporate governance and executive compensation matters. We believe an annual vote would be the best governance practice for our Company at this time.

**Therefore, the Board of Directors believes that holding the executive compensation advisory vote every year is in the best interests of the Company and its stockholders and recommends voting for a frequency of every ONE YEAR .**

**Table of Contents**

**TRANSACTIONS WITH RELATED PERSONS**

Since January 1, 2018 we have engaged in the following transactions in which the amount involved in the transaction exceeds \$120,000 and in which any of our directors or executive officers or their immediate family members or beneficial owners of more than 5% of our voting securities had or will have a direct or indirect material interest. We believe that all of these transactions were on terms no less favorable as could have been obtained from unrelated third parties.

**Consulting Agreement with Michael Giordano**

On December 1, 2017, we entered into a consulting agreement with Michael Giordano, who was subsequently elected to our board of directors in March 2018. Under the agreement, Dr. Giordano agreed to provide consulting and advisory services related to epigenetics and our research, discovery and development portfolio. Under the agreement, Dr. Giordano agreed to work approximately 16 to 20 hours a week, and we agreed to pay him consulting fees of approximately \$12,000 per week. We also agreed to reimburse Dr. Giordano for his travel expenses. The agreement was allowed to be terminated immediately by us in the event of an uncurable breach or at any time with thirty days prior written notice to Dr. Giordano, and by Dr. Giordano with thirty days prior written notice to us in the event we breached the agreement and failed to cure the breach within thirty days of receipt of notice of breach. Dr. Giordano also agreed that, during the term of the agreement and for one year following the expiration or termination of the agreement, he would not work as an employee or consultant for a third party on a project in which we are directly and actively involved or which concerns a therapeutic product or product candidate in our research, discovery and development portfolio, or as a result of which Dr. Giordano's responsibilities to us would be materially limited. Although the initial term of the agreement ended on March 31, 2018, we and Dr. Giordano agreed to extend the term of the agreement until August 31, 2018. We terminated Dr. Giordano's consulting agreement on December 31, 2018.

**Participation in October 2018 Public Offering**

In October 2018, we sold 9,583,334 shares of our common stock at a price to the public of \$9.00 per share pursuant to an underwritten public offering, which we refer to as our October 2018 offering. In our October 2018 offering, New Enterprise Associates 13 L.P., which was a beneficial owner of more than 5% of our voting securities prior to the October 2018 offering, purchased an additional 416,667 shares of our common stock, for approximately \$3.75 million, through the underwriters at the public offering price.

Redmile Group, LLC, which was not a beneficial owner of more than 5% of our voting securities prior to the October 2018 offering, purchased in our October 2018 offering 3,888,889 shares of our common stock, for approximately \$35.0 million, through the underwriters at the public offering price, which purchase resulted in Redmile Group, LLC becoming a beneficial owner of more than 5% of our voting securities following the October 2018 offering.

**Policies and Procedures for Related Person Transactions**

Our board of directors has adopted a written related person transaction policy to set forth policies and procedures for the review and approval or ratification of related person transactions. This policy covers any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, the amount involved exceeds \$120,000, and one of our executive officers, directors, director nominees or 5% stockholders, or their immediate family members, each of whom we refer to as a related person, had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person.





**Table of Contents**

If a related person proposes to enter into such a transaction, arrangement or relationship, which we refer to as a related person transaction, the related person must report the proposed related person transaction to our general counsel, or if we do not have a general counsel, our chief financial officer. The policy calls for the proposed related person transaction to be reviewed and, if deemed appropriate, approved by our audit committee. Whenever practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the audit committee will review, and, in its discretion, may ratify the related person transaction. The policy also permits the chairman of the audit committee to review and, if deemed appropriate, approve proposed related person transactions that arise between audit committee meetings, subject to ratification by the audit committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually.

A related person transaction reviewed under the policy will be considered approved or ratified if it is authorized by the audit committee after full disclosure of the related person's interest in the transaction. As appropriate for the circumstances, the audit committee will review and consider:

the related person's interest in the related person transaction;

the approximate dollar value of the amount involved in the related person transaction;

the approximate dollar value of the amount of the related person's interest in the transaction without regard to the amount of any profit or loss;

whether the transaction was undertaken in the ordinary course of our business;

whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third party;

the purpose of, and the potential benefits to us of, the transaction; and

any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.

Our audit committee may approve or ratify the transaction only if it determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests. Our audit committee may impose any conditions on the related person transaction that it deems appropriate.

In addition to the transactions that are excluded by the instructions to the SEC's related person transaction disclosure rule, our board of directors has determined that the following transactions do not create a material direct or indirect interest on behalf of related persons and, therefore, are not related person transactions for purposes of this policy:

interests arising solely from the related person's position as an executive officer of another entity whether or not the person is also a director of the entity, that is a participant in the transaction, where the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity, the related person and his or her immediate family members are not involved in the negotiation of the terms of the transaction and do not receive any special benefits as a result of the transaction and the amount involved in the transaction is less than the greater of \$200,000 or 5% of the annual gross revenues of the company receiving payment under the transaction; and

a transaction that is specifically contemplated by provisions of our certificate of incorporation or by-laws. The policy provides that transactions involving compensation of executive officers shall be reviewed and approved by our compensation committee in the manner specified in the compensation committee's charter.

**Table of Contents****PRINCIPAL STOCKHOLDERS**

The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our common stock as of March 31, 2019 by:

each of our directors;

each of our named executive officers;

all of our current directors and executive officers as a group; and

each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock.

The column entitled "Percentage Beneficially Owned" is based on a total of 90,803,078 shares of our common stock outstanding as of March 31, 2019.

Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days of March 31, 2019 or shares of restricted stock that vest within 60 days of March 31, 2019 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Epizyme, Inc., 400 Technology Square, Cambridge, Massachusetts 02139.

Name of Beneficial Owner	Number of Shares Beneficially Owned	Percentage Beneficially Owned
<b>5% Stockholders:</b>		
PRIMECAP Management Company (1)	9,556,527	10.5%
Palo Alto Investors, LLC (2)	6,935,074	7.6%
Redmile Group, LLC (3)	6,637,278	7.3%
Entities affiliated with New Enterprise Associates (4)	6,460,851	7.1%
Blackrock, Inc. (5)	5,193,287	5.7%
<b>Directors and Named Executive Officers:</b>		
David M. Mott (6)	6,543,422	7.2%
Beth Seidenberg, M.D. (7)	3,914,446	4.3%
Carl Goldfischer, M.D. (8)	3,450,783	3.8%
Richard F. Pops (9)	69,832	*

Edgar Filing: Epizyme, Inc. - Form DEF 14A

Andrew R. Allen, M.D., Ph.D. (10)	62,499	*
Kenneth Bate (11)	62,499	*
Kevin Conroy (12)	29,440	*
Michael F. Giordano, M.D. (13)	7,291	*
Robert B. Bazemore (14)	969,506	1.1%
Matthew Ros (15)	189,676	*
Shefali Agarwal (16)	32,894	*
All current executive officers and directors as a group (11 persons) (17)	15,332,288	16.6%

**Table of Contents**

- \* Represents beneficial ownership of less than one percent of our outstanding common stock.
- (1) PRIMECAP Management Company has sole voting power with respect to 9,040,927 shares of common stock and sole dispositive power with respect to 9,556,527 shares of common stock. The information reported is based on a Schedule 13G/A, as filed with the SEC on February 8, 2019. The principal business address of PRIMECAP Management Company is 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105.
  - (2) Palo Alto Investors, LLC ( PAI ) has shared voting and dispositive power over all of its shares of common stock. The information reported is based on a Schedule 13G/A, as filed with the SEC on February 14, 2019. The principal business address of PAI is 470 University Avenue, Palo Alto, CA 94301.
  - (3) Redmile Group, LLC ( Redmile ) has shared voting and dispositive power over all of its shares of common stock. The information reported is based on a Schedule 13G/A, as filed with the SEC on February 14, 2019. The principal business address of Redmile is One Letterman Dr, Building D, Suite D3-300, The Presidio of San Francisco, CA 94129.
  - (4) Consists of 6,471,018 shares of common stock held of record by New Enterprise Associates 13, L.P. ( NEA13 ) and 406,500 shares of common stock held of record by Growth Equity Opportunities Fund II, LLC ( GEO II ). NEA Partners 13, L.P. ( NEA Partners 13 ) is the sole general partner of NEA 13 and NEA 13 GP, LTD ( NEA 13 LTD ) is the sole general partner of NEA Partners 13. NEA 13 is the sole member of GEO II. The individual directors (collectively, the NEA 13 Directors ) of NEA 13 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Patrick J. Kerins, Krishna S. Kolluri, David M. Mott, a member of our board of directors, Scott D. Sandell, Ravi Viswanathan and Harry R. Weller. The NEA 13 directors share voting and dispositive power with regard to the shares directly held by NEA 13. The information reported is based on a Schedule 13D/A filed with the SEC on January 19, 2016 and Form 4 filed by Mr. Mott with the SEC on October 5, 2018. The principal business address of New Enterprise Associates, Inc. is 1954 Greenspring Drive, Suite 600, Timonium, MD 21093.
  - (5) BlackRock, Inc. holds sole dispositive power over 5,193,287 of its shares of common stock, and holds sole voting power over 5,066,159 shares of common stock. The information reported is based on a Schedule 13G/A, as filed with the SEC on February 4, 2019. BlackRock Inc.'s principal business address is 55 East 52nd Street, New York, NY 10055.
  - (6) Consists of the shares described in note (4) above, 12,088 shares of common stock held by Mr. Mott, 651 shares of common stock held by the David Mott Declaration of Trust dated May 31, 2001 as amended (the Mott Trust ) and 69,832 shares of common stock which may be acquired by Mr. Mott upon the exercise of options that are exercisable within 60 days after March 31, 2019. Mr. Mott disclaims beneficial ownership of the shares in the Mott Trust except to the extent of any pecuniary interest therein. Mr. Mott is a general partner of New Enterprise Associates, and a member of the board of directors of NEA Management Company, LLC and NEA 13 LTD, which is the general partner of NEA Partners 13, and NEA Partners 13 is the general partner of NEA 13, and as such Mr. Mott may be deemed to share voting and dispositive power with respect to all shares held by these entities. Mr. Mott disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
  - (7) Consists of 6,447 shares of common stock, 69,832 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019 and shares held by certain entities associated with Kleiner Perkins Caufield & Byers ( KPCB ) because, as a partner of KPCB, Dr. Seidenberg may be deemed to share voting and dispositive power with respect to all shares held by entities associated with KPCB. Shares beneficially owned by KPCB consists of 3,838,167 shares of common stock held by Kleiner Perkins Caufield & Byers XIII, LLC ( KPCB XIII ) and 277,388 shares of common stock beneficially owned by individuals and entities associated with KPCB (collectively, KPCB Direct ). All shares are held for convenience in the name of KPCB Holdings, Inc. as nominee, for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The managing member of KPCB XIII is KPCB XIII Associates, LLC ( KPCB XIII

Edgar Filing: Epizyme, Inc. - Form DEF 14A

Associates ), which has the sole voting and dispositive power over the shares held by KPCB XIII. Brook H. Byers, L. John Doerr, Joseph Lacob, Raymond J. Lane and Theodore E. Schlein, the managing directors of KPCB XIII Associates, LLC, and Dr. Seidenberg, a member of our board of directors and of KPCB XIII Associates, exercise shared voting and dispositive control over the shares directly held by KPCB XIII. Dr. Seidenberg disclaims beneficial

---

**Table of Contents**

- ownership of all shares held by KPCB XIII except to the extent of her pecuniary interest therein. The principal business address for all entities and individuals affiliated with Kleiner Perkins Caufield & Byers is 2750 Sand Hill Road, Menlo Park, CA 94025. The information reported is based on a Form 4 filed by Dr. Seidenberg with the SEC on July 2, 2018 and Schedule 13/G, as filed with the SEC on February 13, 2019.
- (8) Consists of 3,380,951 shares of common stock held by entities affiliated with Bay City Capital, LLC including Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. and 69,832 shares of common stock which may be acquired by Dr. Goldfischer upon the exercise of options that are exercisable within 60 days after March 31, 2019. Bay City Capital Management V LLC ( GP V ) is the general partner of Bay City Capital Fund V, L.P. and Bay City Capital Fund V Co-Investment Fund, L.P. (collectively, BCC V ). Bay City Capital LLC ( BCC LLC ) is the manager of GP V. Dr. Goldfischer is an investment partner and managing director of BCC LLC and shares voting and dispositive power with respect to shares held by BCC V. Dr. Goldfischer disclaims beneficial ownership of these shares, except to the extent of any pecuniary interest therein.
  - (9) Consists of 69,832 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.
  - (10) Consists of 62,499 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.
  - (11) Consists of 62,499 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.
  - (12) Consists of 26,562 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.
  - (13) Consists of 7,291 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.
  - (14) Consists of 888,318 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.
  - (15) Consists of 152,845 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.
  - (16) Consists of zero shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.
  - (17) Consists of 1,479,342 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2019.

**Table of Contents**

**SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE**

Section 16(a) of the Exchange Act requires our directors, executive officers, and persons holding more than 10% of our common stock to report their initial ownership of the common stock and other equity securities and any changes in that ownership in reports that must be filed with the SEC. The SEC has designated specific deadlines for these reports, and we must identify in this proxy statement those persons who did not file these reports when due.

Based solely on a review of reports furnished to us, or written representations from reporting persons, we believe all directors, executive officers, and 10% owners timely filed all reports regarding transactions in our securities required to be filed for 2018 by Section 16(a) under the Exchange Act.

**REPORT OF THE AUDIT COMMITTEE**

The audit committee is appointed by the board of directors to assist the board of directors in fulfilling its oversight responsibilities with respect to (1) the integrity of Epizyme's financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory requirements, (2) the qualifications, independence, and performance of Epizyme's independent registered public accounting firm, (3) the performance of Epizyme's internal audit function, if any, and (4) other matters as set forth in the charter of the audit committee approved by the board of directors.

Management is responsible for the preparation of Epizyme's financial statements and the financial reporting process, including its system of internal control over financial reporting and its disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an audit of Epizyme's financial statements in accordance with the standards of the Public Company Accounting Oversight Board, or PCAOB, and issuing a report thereon. The audit committee's responsibility is to monitor and oversee these processes.

In connection with these responsibilities, the audit committee reviewed and discussed with management and the independent registered public accounting firm the audited consolidated financial statements of Epizyme for the fiscal year ended December 31, 2018. The audit committee also discussed with the independent registered public accounting firm the matters required to be discussed by the AS No. 1301, *Communication with Audit Committees*. In addition, the audit committee received written communications from the independent registered public accounting firm confirming their independence as required by the applicable requirements of the PCAOB and has discussed with the independent registered public accounting firm their independence.

Based on the reviews and discussions referred to above, the audit committee recommended to the board of directors that the audited consolidated financial statements of Epizyme be included in Epizyme's annual report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the SEC.

THE AUDIT COMMITTEE OF THE BOARD OF

DIRECTORS OF EPIZYME, INC.

Carl Goldfischer, M.D., Chairman

Kenneth Bate

Richard F. Pops



April 18, 2019

---

**Table of Contents**

**HOUSEHOLDING**

Some banks, brokers and other nominee record holders may be participating in the practice of householding proxy statements and annual reports. This means that only one copy of our documents, including the Notice of Internet Availability of Proxy Materials or, if requested, the 2018 Annual Report and proxy statement, may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of any of the above documents to you upon written or oral request to Epizyme, Inc., 400 Technology Square, Cambridge, Massachusetts 02139, Attention: IR, telephone: 617-229-5872. If you want to receive separate copies of the Notice of Internet Availability of Proxy Materials, proxy statement or annual report to stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address and phone number.

**STOCKHOLDER PROPOSALS**

A stockholder who would like to have a proposal considered for inclusion in our 2020 proxy statement must submit the proposal in accordance with the procedures outlined in Rule 14a-8 of the Exchange Act so that it is received by us no later than December 6, 2019. However, if the date of the 2020 annual meeting of stockholders is changed by more than 30 days from the date of the previous year's meeting, then the deadline is a reasonable time before we begin to print and send our proxy statement for the 2020 annual meeting of stockholders. SEC rules set standards for eligibility and specify the types of stockholder proposals that may be excluded from a proxy statement. Stockholder proposals should be addressed to Epizyme, Inc., 400 Technology Square, Cambridge, Massachusetts 02139, Attention: IR.

If a stockholder wishes to propose a nomination of persons for election to our board of directors or present a proposal at an annual meeting but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, our amended and restated by-laws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate Secretary of the stockholder's intention to bring such business before the meeting.

The required notice must be in writing and received by our corporate Secretary at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year's annual meeting. However, in the event that the date of the annual meeting is advanced by more than 20 days, or delayed by more than 60 days, from the first anniversary of the preceding year's annual meeting, a stockholder's notice must be so received no earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of (A) the 90th day prior to such annual meeting and (B) the tenth day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2020 annual meeting of stockholders, the required notice must be received by our corporate Secretary at our principal executive offices no earlier than February 1, 2020 and no later than March 2, 20120.

Table of Contents

**OTHER MATTERS**

Our board of directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this proxy statement are properly brought before the meeting, the individuals named in the proxy intend to use their discretionary voting authority under the proxy to vote the proxy in accordance with their best judgment on those matters.

By Order of the Board of Directors

/s/ Robert Bazemore

Robert Bazemore

*President and Chief Executive Officer*

**Table of Contents**

**Table of Contents**